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Epilepsy is a chronic neurological disorder characterized by the presence of 
unprovoked, recurrent, spontaneous seizures. The GABA hypothesis of epilepsy 
states that a decrease in GABAergic tone leads to an imbalance between 
excitatory and inhibitory transmission and increases seizure susceptibility. The 
extracellular levels of GABA are controlled by the GABA transporters (GATs), 
including the betaine/GABA transporter (BGT1). BGT1 transports both GABA 
and the organic osmolyte, betaine. Inhibitory tone and osmotic balance both play 
roles in controlling neuronal excitability, making BGT1 a potential target for the 
modulation of excitability. Recently, studies utilizing an equipotent inhibitor of 
GAT1 and BGT1, EF1502, and TGB, a GAT1 selective inhibitor, suggested that 
BGT1 inhibition is anticonvulsant.  
Seizures, pain, anxiety, depression, and other neuropsychiatric disorders are 
influenced by the GABAergic system, including modulation by GAT activity. 
However, little is known about the involvement of BGT1. Since BGT1 may be 
involved in the control of osmotic balance and extracellular GABA levels, it has 
the potential to be involved in the modulation of these disorders. The current 
dissertation was designed to test the hypothesis that BGT1 expression plays a 
role in epilepsy, seizure susceptibility, and other neurological disorders, including 





To test the hypothesis that BGT1 expression is involved in epilepsy, a model 
of temporal lobe epilepsy, i.e., status epilepticus (SE), was utilized and BGT1 
mRNA expression determined at several time-points following SE. BGT1 mRNA 
expression was compared to that of the other GATs and osmoprotective genes. 
From these studies, it appears that the expression of BGT1 may be involved in 
the pathogenesis of epilepsy. To test whether BGT1 is involved in the regulation 
of acute seizure susceptibility, four models of seizure threshold were utilized in 
BGT1 KO and WT mice (minimal tonic extension, minimal clonic, 6 Hz, and 
i.v.PTZ seizure threshold tests). Furthermore, the rate of corneal kindling 
acquisition was ascertained. No differences in seizure threshold were observed 
between genotypes. However, BGT1 KO mice displayed a behavioral profile 
distinct from that of their WT littermate controls. BGT1 KO mice have increased 
depressive and anxiety-like behaviors as well as a ‘manic’ phenotype. The 
results from this dissertation provide evidence in support of continued 
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Epilepsy: a clinical and preclinical challenge 
Epilepsy is a chronic neurological disorder characterized by the presence of 
unprovoked, recurrent, spontaneous seizures. Seizures are symptoms of 
excessive, synchronous neuronal firing. According to the Epilepsy Foundation of 
America (2005), more than 3 million people in the US have epilepsy, and 
200,000 new cases are diagnosed each year, incurring an estimated annual cost 
of $15.5 billion. Despite many years of research, epilepsy remains an ongoing 
clinical challenge. One of the difficulties in treating epilepsy is the heterogeneity 
of the disorder; more than 40 different types of epilepsies and seizure disorders 
exist. Another factor is that the underlying cause of seizures is unknown in 70% 
of cases (Epilepsy Foundation of America, 2005). A third factor contributing to 
the challenge of epilepsy treatment is that only 50% of patients respond to the 
first antiepileptic drug (AED) they are prescribed, and only one-third of the 
remaining population responds to the second AED (Kwan and Brodie 2000). The 
response rate drops precipitously with further medication, resulting in 
pharmacoresistance in approximately 30% of epilepsy patients. If a patient fails 





responding to any subsequent AED (Loscher 2006). The result is an 
unacceptably large proportion of patients who are not adequately treated by 
currently available therapies. Unfortunately, the approval of several new AEDs 
since 1993 has not significantly altered the rate of pharmacoresistance, although 
the pharmacokinetic, safety and side-effect profiles have improved substantially. 
The ongoing challenge of seizure control highlights the need for new AEDs with 
novel mechanisms of action. 
The systemic approach to anticonvulsant drug discovery began in 1937 with 
the discovery of phenytoin using the maximal electroshock model (Putnam and 
Merritt 1937). Since then, several preclinical models have been developed and 
employed in AED discovery (White et al. 2002a). Nonetheless, none of the 
currently available animal models can accurately predict clinical efficacy for every 
compound. Therefore, adequate preclinical testing of a compound requires the 
utilization of several preclinical models that represent different seizure types. 
Each model that was utilized in this dissertation is explained in greater detail in 
the “Mouse models” section of Chapter 1 and in Chapter 3.  
 
 
GABA and GABA transporters 
GABA: γ-aminobutyric acid (GABA) is recognized as the predominant 
inhibitory neurotransmitter in the mammalian brain regulating network 
exciteability (Mody and Pearce 2004). GABA is released from synaptic vesicles 
and acts upon ionotropic GABAA receptors to induce a hyperpolarizing chloride 





efflux to hyperpolarize the neuron (Feldman et al. 1997; Watanabe et al. 2002). 
GABA’s action is terminated by diffusion and re-uptake by GABA transporters 
(GATs). While approximately 80% of released GABA is transported back into the 
presynaptic terminal where it is repackaged for release, the remainder is 
transported into the surrounding astrocytes. Here, GABA is converted via GABA-
transaminase and succinic semialdehyde dehydrogenase to succinate, which 
enters the tricarboxylic acid cycle. Succinate may be metabolized into CO2 or 
converted to α-ketoglutarate and subsequently to glutamine, which can be 
shuttled back to the presynaptic terminal. In the presynaptic terminal, glutamine 
is converted to glutamate, which is then converted into GABA by glutamate 
decarboxylase (GAD); the presence of GAD is the hallmark marker of GABAergic 
neurons (Hertz and Schousboe 1987; Gram et al. 1988; Kugler 1993; Feldman et 
al. 1997).   
GABA transporters: GABA transport is dependent on four transporters, solute 
carrier (SLC) 6a1, SLC6a12, SLC6a13, and SLC6a11, termed GAT1-4 (mice) or 
GAT1, BGT1, and GAT2 and 3 (rat and human). The rat/human nomenclature is 
suggested by the HUGO Gene Nomenclature Committee and will be used 
throughout the remainder of this dissertation.  
Structure and function: The GABA transporters belong to the SLC6 family of 
transporters, which contain 12 transmembrane domains (TMDs) and function as 
dimers (Beleboni et al. 2004). Both the N- and C- termini are intracellular and 
contain phosphorylation sites that function to regulate transport. TMD 1, 





tertiary structure stabilization, and EL 4-6 are believed to be involved in substrate 
binding (Jursky et al. 1994; Kanner 1994; Tamura et al. 1995). Sequence 
alterations in these ELs lead to mutants with predictable transport kinetics and 
substrate specificity. For example, substituting the sequence for GAT2 into EL6 
of GAT1 leads to a Km of GABA similar to that of GAT2. Substituting the GAT3 
sequence into EL5 of GAT1 enables the transport of β-alanine through the 
mutant, while native GAT1 cannot transport β-alanine (Tamura et al. 1995). Site-
directed mutagenesis has found five residues essential for transport activity 
(R69, W68, E101, Y140, and W222), and tyrosine-140 is also imperative for 
GABA binding. Transport requires minimal lengths of IL4 and EL4 (Bismuth et al. 
1997; Schousboe and Kanner 2002).  
SLC6 transporters are Na+ and Cl- dependent, and are driven by the electrical 
gradient of Na+. GAT1 transports 2 Na+ and 1 Cl-, while BGT1 transports 3 Na+ 
and 1 Cl- with each molecule of substrate (Matskevitch et al. 1999). The GATs 
are able to maintain a large gradient (105) between intra- and extracellular GABA 
(Beleboni et al. 2004). Since the transporters are driven by an electrogenic 
mechanism, they are able to reverse transport under certain conditions. When 
the membrane potential is more negative than the reversal potential of the 
transporter, it will function in the forward (inward) direction, while it will function in 
reverse if the membrane potential is above the reversal potential. Due to this, an 
increase in intracellular Na+ or strong depolarization can reverse GATs 
(Richerson and Wu 2003). The ability of GATs to reverse and release GABA into 





preventing seizure spread (Patrylo et al. 2001). Patients with epilepsy have 
reduced seizure-induced increases in extracellular GABA, perhaps due to the 
downregulation of GATs (During et al. 1995).   
Localization: GAT1: GAT1 is abundant in the brain and displays a wide 
distribution pattern that is consistent with the labeling of GABAergic neurons. It is 
found in high levels in the retina, olfactory bulb, ventral pallidum, interpeduncular 
nucleus, cortex, hippocampus, and cerebellum (Durkin et al. 1995; Borden 1996). 
GAT1 is absent on cell bodies: it is located on axonal segments of presynaptic 
GABAergic neurons where it is integral for the presynaptic reuptake of released 
GABA (Radian et al. 1990; Borden 1996; Conti et al. 1998).  
BGT1: Mouse BGT1 was originally cloned and referred to as GAT2. It was 
determined to be the mouse homologue to canine and human BGT1 (88% and 
87% sequence homology, respectively) (Lopez-Corcuera et al. 1992; Borden et 
al. 1995a). Mouse GAT2 is therefore termed BGT1 in this report as suggested by 
the HUGO Gene Nomenclature Committee. BGT1 mRNA is widely distributed 
throughout the brain (Lopez-Corcuera et al. 1992; Borden et al. 1995a).  
However, BGT1 protein expression patterns in vivo are currently unvalidated, in 
part due to the absence of knockout data and to questionable antibody 
specificity. Using available antibodies, BGT1 was reported to be expressed on 
neurons, and to be located extrasynaptically, but not necessarily in close 
proximity to GABAergic synapses (Zhu and Ong 2004b). BGT1 has been 
localized mainly to astrocytes based on in vitro mRNA and pharmacological 





situ hybridization studies suggest mostly neuronal expression (Borden 1996). 
BGT1 and GAT1 are expected to be differentially localized due to their 
basolateral and apical expression, respectively, in polarized epithelial cells (Ahn 
et al. 1996). The basolateral expression of BGT1 suggests either a post- or extra-
synaptic action (Borden 1996). In situ hybridization studies and microinjection of 
cDNA into cultured hippocampal cells suggest that BGT1 is not localized 
exclusively to GABAergic synapses (Borden et al. 1995a; Ahn et al. 1996). Due 
to the supposed extrasynaptic location of BGT1, it is not likely to be contributing 
to the termination of fast, phasic neurotransmission. It is more likely playing a 
role in tonic inhibition (Mody 2001). It has also been suggested that BGT1 is not 
functionally important as a GABA transporter, but that its major role in the brain is 
to serve as an osmolyte transporter.  
GAT2: GAT2 is expressed abundantly in the neonatal brain and at very low 
levels in the mature brain. It is found in both neurons and astrocytes, primarily 
extrasynaptically. GAT2 is also found in the leptomeninges, and is believed to 
play a role in the regulation of cerebrospinal fluid GABA levels (Durkin et al. 
1995; Borden 1996; Conti et al. 1999).   
GAT3: GAT3 is abundantly expressed and widely distributed in the brain, 
albeit less so than GAT1. Although it is expressed in neurons and astrocytes, it is 
primarily localized to astrocytic processes. GAT3 is found near GABAergic 
synapses, and is believed to participate in the reuptake of presynaptically 
released GABA (Durkin et al. 1995; Minelli et al. 1996; Ribak et al. 1996a, b; De 





GAT inhibition as a therapeutic target: The role of GABA and GATs in several 
disease states will be discussed in the section entitled “GABA and GATs in 
disease.” The effects associated with GAT inhibition are inherently complicated. 
A grossly oversimplified view is that GAT inhibition will increase extracellular 
GABA and therefore be anticonvulsant, antidepressive, anxiolytic, analgesic, and 
antipsychotic. However, many complicating factors exist. GATs have a variety of 
functions: (1) termination of inhibitory postsynaptic potentials (IPSPs) (Dingledine 
and Korn 1985; Roepstorff and Lambert 1994; Draguhn and Heinemann 1996; 
Engel et al. 1998), (2) supplication of GABA back to axon terminals for reuse 
(Schousboe et al. 1983), (3) elimination of GABA from diffuse extracellular 
spaces (Frahm et al. 2001), and (4) nonvesicular release of GABA by reverse 
transport (Schwartz 1987; Belhage et al. 1993; Gaspary et al. 1998). While re-
use and release of GABA enhance inhibition, IPSP termination and reuptake of 
GABA reduce inhibition. Therefore, the net effect of GAT inhibition is not always 
foreseeable, and reduced GABA uptake has been shown to have both anti- and 
proconvulsive effects (During et al. 1995; Patrylo et al. 2001). Tiagabine (TGB), a 
specific GAT1 inhibitor, may be prescribed as an anticonvulsant, anxiolytic or 
antidepressant, but it may produce anxiety and depression as side effects in 
some patients (Kalviainen 2001). Furthermore, it is proconvulsant at high doses 
and at certain stages of development (Trinka et al. 1999; Balslev et al. 2000). 
The GAT1 KO mouse has been reported to experience both decreased (Liu et al. 
2007) and increased (Chiu et al. 2005) anxiety. The aforementioned conflicting 





limit the ability to accurately predict experimental outcomes. However, the clinical 
utility of TGB against a host of neurological disorders supports the use of GAT 
inhibition as a therapeutic target.  
GAT inhibitors: Each GAT transports GABA with a different affinity and 
possesses a distinct endogenous substrate profile, as shown in Table 1.1. 
Historically, GABA analogs have been utilized in the search for specific GAT 
inhibitors. Muscimol is a naturally-occurring GABA analog that interacts with 
GABA receptors, transporters, and GABA-transaminase (Krogsgaard-Larsen et 
al. 1975). The realization of the potential of muscimol led to synthesis of analogs 
with preferential activity towards GABA receptors (THIP (Krogsgaard-Larsen et 
al. 1977; Krogsgaard-Larsen et al. 2000)) or transporters (THPO, a β-alanine 
analog (Krogsgaard-Larsen and Johnston 1975; Schousboe et al. 1981)). The 
synthesis of THPO facilitated the discovery of its cyclic amino acid parents, 
nipecotic acid and guvacine, which are naturally-occurring GAT inhibitors with no 
receptor activity (Krogsgaard-Larsen and Johnston 1975). These compounds 
served as major lead compounds for the development of specific GABA transport 
inhibitors. While nipecotic acid and guvacine are substrates for GATs, the 
analogs based off of their chemical structure are not (Clausen et al. 2006). 
Unfortunately, attempts to discover/synthesize GAT-specific inhibitors that do not 
have affinity for GAT1 has proven difficult, as discussed further in Chapter 4. The 
most specific pharmacological inhibitors of the GATs are presented in Table 1.1. 
A much more detailed reference about the evolution of GABA transport inhibitors 








Table 1.1: Endogenous GAT substrates and synthesized GAT inhibitors in 
transfected mouse cells (IC50, µM unless otherwise noted) 
 GAT1 BGT1 GAT2 GAT3 
GABA 17 a 51 a 15 a 17 a 
Taurine - b - b 540 b 1400 b 
β-alanine - b - b 28 b 99 b 
Betaine - b 200 b - b - b 
Tiagabine 0.8 300 >300 800 
R,S-EF1502 7  26 >300 >300 
R-EF1502 4 22 >150 >150 
S-EF1502 120 34 >150 >150 
SNAP-5114 >300 c 22 c 20 c 6.6 c 
NNC-005 2090 19 c 1.4 c 41 c 15 c 
 
Table 1: aKm; bxenopus oocytes; cRat. References: (Lopez-Corcuera et al. 1992; 
Liu et al. 1993; Borden 1996; Thomsen et al. 1997; Schousboe and Kanner 








While TGB has proven to be valuable clinically, its use is limited by a less 
than ideal pharmacokinetic profile (i.e., short half-life that mandates dosing three 
times a day) and side effects (dizziness, fatigue, confusion) (Genton et al. 2001). 
A better-tolerated GABA uptake inhibitor is therefore desirable. EF1502 (N- [4,4-
bis(3-methyl-2-thienyl)-3-butenyl]-4-(methylamino-4,5,6,7-tetrahydrobenzo 
[d]isoxazol-3-ol) is a compound that has approximately equal potency for GAT1 
and BGT1. When EF1502 was co-administered with TGB, a synergistic 
anticonvulsant effect was observed in the absence of enhanced toxicity (White et 
al. 2005; Madsen et al. 2009). Furthermore, electrophysiological studies 
determined that EF1502 decreases spontaneous interictal-like bursting frequency 
in a hyperexcitable medium, while TGB fails to do so (Smith et al. 2008), 
demonstrating that the BGT1 action of EF1502 may be functional and may 
contribute to its anticonvulsant mechanism. The potential ability to target tonic 
inhibition selectively with BGT1 inhibition due to its presumed extrasynaptic 
localization suggests that there may be a way to realize the therapeutic effects of 
BGT1 inhibition without severe disruption of cognitive or behavioral functions, 
thereby creating a desirable therapeutic profile. 
GABA and GATs in disease: GABA and GATs are known to be involved in 
several diseases as discussed below. 
Epilepsy: The GABA hypothesis of epilepsy states that a decrease in 
GABAergic tone leads to an imbalance between excitatory and inhibitory 
transmission and increases seizure susceptibility. Pharmacologically increasing 





proconvulsant (Meldrum et al. 1980). GAT1 is the target of the clinically utilized 
anticonvulsant TGB and is known to be important in controlling neuronal 
excitability. Therefore, despite the complex nature of GAT inhibition, the existing 
clinical data do support the utilization of GAT inhibition as a therapeutic strategy. 
It has been shown that anticonvulsants working through enhanced inhibition of 
astrocytic GABA transport are more effective and less toxic than those working 
preferentially on neuronal GABA transport (White et al. 2002b), supporting the 
development of agents targeting non-GAT1-mediated transport. In point, the 
GAT1 over-expressing mouse has increased seizure susceptibility (Ma et al. 
2001; Zhao et al. 2003), consistent with decreased available GABA. However, 
the GAT1 KO mouse was also shown to have slightly increased seizure 
susceptibility in a small study (Chiu et al. 2005). This result was unexpected, as 
the KO mouse has massively increased tonic conductance (Jensen et al. 2003; 
Xu et al. 2007). This result may reflect the inability of the neuron to take up 
extracellular GABA for subsequent release. Another possible factor is that GAT1 
was found to negatively regulate T-cell-mediated immune response in the CNS, 
and GAT 1 KO mice have an exacerbated inflammatory response post- 
experimental encephalitis (Wang et al. 2008). Because neuroinflammation 
contributes to epileptogenesis, GAT-mediated immune system modulation may 
contribute to the seizure susceptibility of the GAT1 KO mouse.  
GAT alterations have been shown to exist in epilepsy and are discussed in 
the Introduction of Chapter 2.  Although GAT1 expression is decreased in 





al. 2003; Stief et al. 2005). This result supports the following statements: (1) 
GAT1 is nonetheless functional in epilepsy, (2) GAT inhibition is still a viable 
target, and (3) GATs are not usually working at full capacity (Dalby 2000; Keros 
and Hablitz 2005). And so the existing evidence suggests that GATs modify 
seizures, and seizures alter GATs.  
Pain: GABAergic modulation is important in pain as well as epilepsy; in fact, 
drugs originally marketed as anticonvulsants are becoming increasingly utilized 
for their antinociceptive potential. Pregabalin, gabapentin, TGB, carbamazepine, 
and valproic acid are all prescribed for different varieties of pain and possess a 
mechanism of action involving GABA modulation (Landmark 2007). Of particular 
interest to this investigation is the observation that TGB, which is an effective 
treatment for migraine (Landmark 2007), sensory neuropathy (Novak et al. 
2001), tonic spasm (Solaro and Tanganelli 2004), bruxism (Kast 2005), and 
chronic pain (Todorov et al. 2005), exerts its clinical effects through direct and 
selective inhibition of GAT1. GABA (Castro-Lopes et al. 1993; Ibuki et al. 1997; 
Eaton et al. 1998) and GABA receptor (Bhisitkul et al. 1990; Castro-Lopes et al. 
1995) levels are decreased following axotomy and chronic constriction injury, 
implicating that a functional loss of GABA in the dorsal horn leads to the 
development of neuropathic pain in animal models. Activation of both GABAA and 
GABAB receptors in the spinal cord is analgesic (Jasmin et al. 2004). 
Unfortunately, GABA receptor agonists possess undesirable side effects (Jasmin 
et al. 2004), warranting the development of GABAergic drugs with different 





the spinal cord and produces analgesia by reducing the evoked release, not 
basal levels, of the pain-enhancing excitatory amino acids aspartate and 
glutamate (Meller et al. 1996; Smith et al. 2007). Furthermore, a decrease in 
GAT1 expression results in hypoalgesia (Xu et al. 2008) while upregulation is 
hyperalgesic (Ng and Ong 2001; Hu et al. 2003). GAT1 is upregulated following 
chronic constriction injury and contributes to pain behavior (Daemen et al. 2008). 
As the ability of GAT1 inhibition to decrease pain is attributed to a direct increase 
in GABA levels, it is possible that non-GAT1 inhibitors will possess 
antinociceptive or analgesic actions as well. GAT1 inhibition is relatively well 
tolerated; however, side effects are observed. Non-GAT1 (i.e., BGT1) inhibition 
may potentially incur a decreased incidence of side effects due to its supposed 
effect on tonic inhibition rather than phasic neurotransmission.  
Depression: GABAergic neurotransmission is also recognized to be an 
important modulator in depression. Patients with depression have lower levels of 
plasma, cerebrospinal fluid, and brain GABA , as well as a decreased density of 
GABAergic neurons in the orbitofrontal cortex (Rajkowska et al. 1999; Sanacora 
et al. 1999, 2000; Krystal et al. 2002). Preclinical data reveal that animals that 
have been exposed to a depressive stimulus (a learned helplessness paradigm) 
have a reduced release of GABA and a decreased influx of chloride in several 
brain areas (Petty and Sherman 1981; Borsini et al. 1988; Drugan et al. 1989; 
Gomez et al. 2003; Briones-Aranda et al. 2005). In agreement with these data, 
GABA release and chloride uptake are increased following pharmacological 





Kram et al. 2000; Gomez et al. 2003; Herman et al. 2003; Yang and Shen 2005). 
Clinical studies have provided some evidence of efficacy for several GABAergic 
drugs for the treatment of depression, including valproic acid, vigabatrin, 
gabapentin, and TGB (Kalueff and Nutt 2007).  The modulation of depression by 
GAT1 is demonstrated not only by the efficacy of TGB, but also by the reduced 
susceptibility to a learned helplessness paradigm of GAT1 KO mice compared to 
WT controls (Liu et al. 2007).  The effect of non-GAT1 inhibition on depression 
has not been determined.  
Anxiety: Anxiety is also associated with GABAergic dysfunction (Nutt and 
Malizia 2001; Lydiard 2003; Nemeroff 2003). In humans and animal models, 
GABA receptor activation is anxiolytic while antagonism produces anxiety 
(Kalueff and Nutt 1996). In complement to this, valproic acid, vigabatrin, and TGB 
are clinically effective anxiolytics (Lang and de Angelis 2003; Nemeroff 2003; 
Rosenthal 2003; Stahl 2004). The modulation of anxiety by GAT1 is supported by 
the anxiolytic efficacy of TGB and also by the GAT1 KO mouse, which has been 
reported to display decreased anxiety compared to WT mice (Liu et al. 2007).   
Neuropsychiatric disorders: Several neuropsychiatric disorders involve 
dysfunction of the GABAergic system. Of particular relevance to this proposal are 
diseases involving a manic phase, such as bipolar disorder and schizophrenia. 
Schizophrenia has been associated with decreased interneuron and GABAergic 
terminal numbers, decreased GABA receptor binding affinity, and altered input 
into GABAergic cells (Benes and Berretta 2001). The GABA hypothesis of 





dopaminergic neurons is responsible for the disorder (Koran 1976; Wolkowitz 
and Pickar 1991). Selective loss of nonpyramidal neurons in CA2 of the 
hippocampus has been described in schizophrenia and bipolar disorder (Benes 
et al. 1998; Todtenkopf et al. 2005). Although it is accepted that there is a 
decrease in GABAergic functioning in various neuropsychiatric disorders, the 
responsible mechanisms are fundamentally different, and clear endophenotypes 
involving the GABA system exist for each disorder (Benes 2007). The 
involvement of the GABA system in neuropsychological disorders is highly 
complex, but it remains evident that GABA modulation is a rational strategy for 
the treatment of these disorders. GABA-modulating drugs are clinically 
efficacious against schizophrenia (Wassef et al. 1999) and bipolar disorder 
(Bowden 1998). TGB has been determined inappropriate for the treatment of 
acute mania (Carta et al. 2002). Beyond this, however, there have been no 
adequate clinical studies regarding the use of TGB for neuropsychiatric 
disorders. One small randomized, double-blind, placebo-controlled study and a 
limited number of case studies suggest possible efficacy (Kaufman 1998; Vieta et 
al. 2006); nonetheless, it is important to note that any firm conclusion regarding 
the efficacy of TGB in neuropsychiatric disorders will necessarily have to be 
provided by appropriate double-blinded, placebo-controlled clinical trials. The 
utility of non-GAT1 inhibitors has not been determined for any of these disorders.  
As can be readily deduced from the above discussion, GAT inhibition has the 
potential to be useful in the treatment of several diverse neurological disorders. 





disorders, it remains to be determined if inhibition of the other GATs, including 
BGT1, would provide a therapeutic benefit as well.  
 
 
Osmoregulation and osmolyte transporters 
Functions of betaine: Betaine is found ubiquitously in nature in animals, 
plants, and microorganisms. Betaine serves two main functions: to serve as an 
organic osmolyte and as a source of methyl groups. Betaine is accumulated in 
higher organisms mostly through the diet. Wheat, spinach, seafood, and beets 
contain high amounts of betaine, and the average daily intake for humans is 1 
g/day. Although 9-15 g/day has been reported to be safe, 3-6 g/day for more than 
4 weeks has produced cerebral edema in children (Yaghmai et al. 2002; Devlin 
et al. 2004). Betaine is absorbed rapidly (1-2 h) into the body through BGT1 and 
amino acid transport system A and resting serum concentrations are 20-70 µM 
(Lever et al. 1994; Peters-Regehr et al. 1999; Schwahn et al. 2003). In rats, 
plasma concentrations are approximately 190 µM, while the brain concentration 
is near 50 µM (Slow et al. 2009). Both BGT1 and amino acid transport system A 
also are present at the BBB (Smith 2000; Takanaga et al. 2001). Betaine is also 
formed in the body, predominantly in the liver and kidney, by the oxidation of 
choline. Choline is initially converted to betaine aldehyde by choline 
dehydrogenase in mitochondria. Betaine aldehyde is then converted into betaine 






Betaine is a zwitterionic quaternary ammonium (molecular weight 117.2) and 
is a derivative of the amino acid glycine. It belongs to the family of methylamines 
due to its three chemically reactive methyl groups. These groups allow betaine to 
function as a methyl donor in transmethylation reactions that are important in 
many biochemical pathways. This catabolic transmethylation reaction of betaine 
is catalyzed by betaine homocysteine methyl transferase to form dimethylglycine. 
Betaine that is not catabolized is available to function as an organic osmolyte.  
Many aspects of cellular function are directly affected by osmotic state. These 
functions include protein turnover, pH control, membrane transport systems, 
gene expression, and amino acid, fatty acid, carbohydrate, and ammonia 
metabolism (Haussinger 1996). Osmotic balance is maintained in part by organic 
osmolytes. The initial adaptation process to osmotic stress involves the 
accumulation of low molecular weight inorganic ions such as K+, Na+, and Cl-. 
While ameliorating the osmotic perturbation, these ions have a destabilizing 
effect on intracellular protein structure and enzymatic function. Therefore, cells 
replace the inorganic ions with organic osmolytes (Petronini et al. 1993; Burg 
1994). Organic osmolytes may also function as a ‘chemical chaperone’ for 
protein folding in a process known as osmotic remediation (Burg 1995). 
Important organic osmolytes in the CNS include taurine, myo-inositol, sorbitol, 
and betaine. The ability of cells to accumulate these depends on the expression 
of the transporter or biosynthetic enzyme specific for each osmolyte: the taurine 





myo-inositol, and BGT1 for betaine. Sorbitol is synthesized intracellularly by the 
enzyme aldose reductase (AR).  
Sodium, potassium, chloride, bicarbonate, glucose and urea are the 
osmotically important body fluid solutes. Resting serum osmolality is 
approximately 285-295 mOsm. Serum osmolality above 380 mOsm produces 
stupor, 400 mOsm leads to generalized tonic clonic seizures, and 420 mOsm is 
fatal (Habel 1999).  
Osmoregulation in epilepsy:  BGT1 not only transports GABA, but also 
betaine (Lopez-Corcuera et al. 1992). Network excitability is directly affected by 
the size of the extracellular space (ECS) (Roper et al. 1992), which is determined 
by cellular size. Osmolytes, such as betaine, accumulate in cells and cause 
water retention to avoid cell shrinkage in hyperosmotic solutions (Yancey et al. 
1982). Excessive neuronal activity causes a hypertonic extracellular 
environment, cell swelling, and ECS reduction (Dietzel et al. 1982). ECS 
reduction magnifies the effects of extracellular molecules because (1) there is 
less volume of dilution, (2) diffusion is slowed due to less space and more 
tortuosity, and (3) electrical conduction is enhanced by increased resistance 
(Schwartzkroin et al. 1998). Accordingly, a reduced ECS is proconvulsant, while 
an enlarged ECS suppresses seizures (Dudek et al. 1990). Since BGT1 can 






Osmolyte transporters in epilepsy: The involvement of osmolyte transporters 
in epilepsy is less clear than that of GATs; however, several associations exist 
and are described in the Introduction of Chapter 2.  
 
The Betaine/GABA transporter 
Regulation: BGT1 is encoded by the SLC6a12 gene. Eight isoforms exist, 
which differ only in their 5’ untranslated regions. By this 5’ end motif, BGT1 is 
grouped into three types; A, B, and C, which are all hypertonicity-inducible in 
MDCK cells and display tissue-specific expression. Type A is expressed in the 
kidney medulla, Type B in the kidney medulla and cortex, brain, and liver, and 
Type C in the kidney medulla and cortex and the brain. The physiological 
significance of these different isoforms is unknown (Takenaka et al. 1995). The 
regulatory mechanisms of SLC6a12 and BGT1 protein expression in the CNS 
have not been elucidated. However, many studies have addressed these 
mechanisms in cell systems outside the CNS, and are the basis for the following 
discussion. Expression of BGT1 is altered by tonicity due to its promotion by the 
transcription factor tonicity-responsive enhancer binding protein (TonEBP), also 
known as osmotic response element-binding protein (OREBP) and nuclear factor 
of activated T-cells 5 (NFAT5). The N-terminus of TonEBP contains its DNA 
binding domain (Stroud et al. 2002), while the C-terminus contains an NaCl 
dependent transactivating domain (Ferraris et al. 2002b). TonEBP binds to 
tonicity-responsive enhancers on the BGT1 gene, TonE1 and TonE2, which act 





1998; Miyakawa et al. 1999a). Synergism suggests that a protein-protein 
interaction that stabilizes DNA binding exists between two TonEBP molecules 
bound to TonE1 and TonE2. Such a complex is commonly seen (Tanaka 1996). 
Under osmotic stress, TonEBP expression increases, and it is translocated to the 
nucleus (Woo et al. 2000a) to promote the osmoprotective genes BGT1, TauT, 
SMIT, and AR.  Expression of BGT1 may be increased by proteins that 
contribute to the activation of TonEBP, including activator protein-1 (Irarrazabal 
et al. 2008), protein kinase A (Ferraris et al. 2002a), phosphatidylinositol 3-kinase 
1A (Irarrazabal et al. 2006), heat shock protein 90 (Chen et al. 2007), p38, and 
Fyn (Ko et al. 2002). In contrast, RNA helicase A (Colla et al. 2006) and 
poly(ADP-ribose) polymerase-1 (Chen et al. 2007) produce an inhibitory action 
on TonEBP transactivating activity. All of the aforementioned targets contribute to 
the regulation of TonEBP, but none is completely necessary. There is extensive 
post-transcriptional control over the surface expression of BGT1. Sorting signals 
and a PDZ association motif are found at the intracellular C-terminus of BGT1 
(Perego et al. 1999). Extracellular calcium can cause internalization of BGT1, 
which may be PKC mediated (Kempson et al. 2006). PKC-mediated 
phosphorylation disrupts the association of BGT1 with the PDZ domain of Lin7 
(Massari et al. 2005), an interaction that is necessary for BGT1 to remain at the 
membrane, but not for it to be targeted to the membrane (Perego et al. 1999). 
PDZ domains anchor transmembrane proteins to the cytoskeleton and tether 
signaling complexes together, and Lin7 is a synaptic protein important in synaptic 





trafficking of cytosolic BGT1 pools were shown to contribute to hypertonicity-
induced BGT1 upregulation (Basham et al. 2001; Kempson et al. 2003). A 
summary of the proposed regulation of BGT1 is shown in Figure 1.1. The 
regulation of the osmoprotective genes in the brain is investigated and discussed 
in Chapter 2.  
Functions in the CNS: It has been suggested that BGT1 may not function to 
remove presynaptically released GABA due to its expression levels, localization, 
and affinity. However, several potential functions for BGT1 in the CNS remain, 
including: 1) osmotic regulation, 2) GABA and/or betaine transport across the 
blood-brain barrier, 3) redistribution of GABA from GABAergic to glutamatergic 
neurons, 4) redistribution of betaine following osmotic stress, 5) functionality as a 
neurotransmitter-gated ion channel. These possible roles for BGT1 are described 
and supported further in the Discussion of Chapter 5.  
 
Mouse models 
Several mouse models were utilized for the studies described in this 
dissertation.  Each model has been validated for the intended purpose in the 
literature, and was validated for use in this laboratory prior to experimental 
testing included in this work. A very brief introduction to each model is presented 











Figure 1.1: The proposed regulation of BGT1 expression in the kidney. TonEBP 
is translocated to the nucleus where it binds to TonE promoter sites to induce the 
transcription of BGT1. Several effectors contribute to the transactivating activity 
of TonEBP: heat shock protein 90 (HSP90), phosphatidylinositol 3-kinase 1A 
(PI3K), protein kinase A (PKA), activating-protein family 1 (AP-1), Fyn, p38, RNA 
helicase A, and poly(ADP-ribose) polymerase 1. BGT1 is maintained at the 
membrane by interaction with Lin7, which is disrupted by protein kinase C (PKC)-




























      Minimal clonic threshold:  The minimal clonic seizure threshold is a measure 
of forebrain seizure threshold. These seizures experimentally present as jaw and 
forelimb clonus and may involve rearing and falling (White et al. 2002a).   
6 Hz psychomotor seizure test/threshold: The 6 Hz test is a model of complex 
partial seizures involving limbic structures. The experimental 6 Hz seizure 
presents as a clonic phase followed by stereotypic, automatistic behaviors such 
as jaw chomping and vibrissae twitching. This test is an acute seizure test that 
displays pharmacoresistance to several of the clinically available AEDs including 
phenytoin, carbamazepine, lamotrigine, and topiramate (White et al. 2002a).  
Maximal electroshock test/minimal tonic extension threshold: The MES test 
represents hindbrain seizures and experimentally manifests as a tonic-extension 
seizure. Drugs that display efficacy in this test are clinically efficacious against 
tonic-clonic seizures (White et al. 2002a). 
Corneal kindling: Corneal kindling produces partial seizures that secondarily 
generalize. This model represents a cost-effective alternative to the highly 
clinically predictive but labor-intensive electrically kindled rat. The validation of 
the corneal kindled mouse model as a pharmacological tool is discussed in detail 
in Chapter 3.  
i.v. pentylenetetrazol (i.v.PTZ) threshold: The i.v.PTZ test is an acute 
chemical test that is used to determine what effect a drug or genetic manipulation 
has on seizure threshold. Seizures are induced by the infusion of PTZ, a GABA 
receptor antagonist. The occurrence of a seizure does not have to be abolished; 





clonus in a population of animals. Hence, it is a highly sensitive parametric 
method for seizure threshold assessment (Orlof 1949). 
Frings mouse: The Frings mouse is a model of sensory evoked reflex 
epilepsy, which usually manifests as primary generalized tonic-clonic seizures. 
These mice experience tonic-extension seizures in response to an audiogenic 
stimulus due to a mutation in the mass1 protein (Skradski et al. 1998). The 
Frings mouse is advantageous to the DBA/2 mouse model of audiogenic 
seizures because DBA/2 mice can only be utilized at a young age (2-4 weeks) 
due to deafness, and also have a high mortality rate following seizure activity (Le 
Gal La Salle and Naquet 1990).  
Pilocarpine-induced status epilepticus: Status epilepticus (SE) is 
characterized by the occurrence of unremitting seizure activity, usually longer 
than 30 min. It can be experimentally induced by administration of a muscarinic 
agonist, pilocarpine. Pilocarpine-induced SE (pilo-SE) leads to pathological 
changes similar to those observed in humans with temporal lobe epilepsy, i.e., 
mossy fiber sprouting, astrogliosis and hippocampal sclerosis, characteristic cell 
loss in the CA1 of the hippocampus, and the development of spontaneous 
seizure activity following a postinsult latent period (2-4 weeks in the mouse pilo-
SE model) (Cavalheiro et al. 1996; Shibley and Smith 2002).  
Forced swim test: The forced swim test involves a preconditioning of animals, 
whereby they are placed in a cylinder of water from which they cannot escape 
prior to the recorded portion of the test. This preconditioning induces 





learned helplessness will give up more quickly than normal animals, and animals 
with antidepressant treatment will swim for a longer period of time (Porsolt et al. 
1977).  
Writhing test: The writhing test is a model of acute somato-visceral pain 
induced by an intraperitoneal injection of dilute acetic acid. A ‘writhe’ is caused 
by a wave of abdominal wall constrictions and elongations, usually accompanied 
by a hindlimb extension. The writhing test is not an inflammatory-mediated 
process, although inflammation does occur (Northover 1963; Collier et al. 1968). 
This test is sensitive to broad range of analgesics, making it an attractive model 
for the initial identification of analgesic agents. However, it is criticized for 
determining analgesic potential in compounds that are nonanalgesic and 
because of the existence of a large number of nonresponders (Siegmund et al. 
1957; Hendershot and Forsaith 1959; Collier et al. 1968; Pearl et al. 1969).  
Carrageenan test: Carrageenan is a linear polysaccharide extracted from 
seaweed that, upon subcutaneous injection, causes hyperalgesia and localized 
inflammation (Hargreaves et al. 1988). Hyperalgesia develops relatively slowly in 
the carrageenan test (h) and involves a phenomenon termed “windup,” in which 
the number of neuronal responses progressively increases (Mendell 1966). 
Windup is involved in the maintenance of inflammatory and neuropathic pain and 
is attributed to responses of spinal dorsal horn neurons evoked by C-fiber 
afterdischarge (Dubner 1986; Gracely et al. 1992). A specific receptor has not 





Formalin test: The formalin test was originally designed for use in rats 
(Dubuisson and Dennis 1977) and later modified for use in mice (Takahashi et al. 
1984). The formalin test has become one of the most commonly used assays for 
chemically induced nociception (Mogil et al. 2001). Formalin injection into the 
plantar region of a hind paw elicits a characteristic biphasic licking of the affected 
paw: the mouse licks its paw for 5-10 min immediately following the injection 
(acute phase or phase 1), followed by a brief latent period where there is little 
activity (usually less than 5 min), followed by a 20-30 min period of licking 
(inflammatory phase or phase 2). The acute phase is believed to be mediated by 
direct nociceptor activation, while the inflammatory phase is attributed 
predominantly to ongoing peripheral afferent input and controversially to central 
sensitization (Dallel et al. 1995; Taylor et al. 1995).  
Tail flick: The tail flick test measures thermal sensitivity utilizing the flexor 
withdrawal reflex. This reflexive behavior in response to thermal pain is predictive 
of compounds with analgesic efficacy in animals (D'Amour and Smith 1941; 
Taber 1973) and humans (Chan and Dallaire 1989).  
Locomotion: Increased locomotor activity in mice is a model of the manic 
phase of neuropsychiatric disorders in humans, which can be induced by 
stimulation of the dopaminergic system (Mamelak 1978; Peet and Peters 1995; 
Anand et al. 2000). In experimental and certain human cases, lithium attenuates 
this effect (Van Kammen and Murphy 1975; Berggren et al. 1978; Huey et al. 





possess inherently altered neurobiology compared to normal rodents, and may 
serve as a genetic model of bipolar disorder or schizophrenia.  
 
Hypothesis and dissertation overview 
The goal of this dissertation was to test the hypothesis that BGT1 expression 
plays a role in epilepsy, seizure susceptibility, and other pathological states. 
Chapter 2 explores the alterations in BGT1 mRNA expression following status 
epilepticus compared to other GABA and osmolyte transporters, as well as 
possible mechanisms regulating the brain expression of BGT1 mRNA. The 
results from these studies suggested that BGT1 expression is involved in 
epilepsy and warranted further investigation into its role in controlling seizure 
activity and possibly other behaviors modulated by GABA. A two-pronged 
approach was utilized for this determination: pharmacological inhibition of BGT1 
and genetic knockout of BGT1. Chapter 3 validates the use of the corneal 
kindling model for pharmacological testing, and Chapter 4 utilizes this test, along 
with several others, to determine if pharmacological inhibition of BGT1 has an 
effect on seizure activity and other GABA-modulated behaviors including pain 
and depression. During the course of investigation, the pharmacological inhibitor 
utilized in Chapter 4 was determined to be nonspecific for BGT1. Therefore, the 
BGT1 KO mouse became the only available tool for accurately testing BGT1’s 
involvement in seizure control and behavior. Data obtained in this investigation 
are presented in Chapter 5. The studies performed in this dissertation illustrate 





such as depression, anxiety, locomotion, and pain; however, as evidenced by 
extensive seizure threshold studies, BGT1 does not appear to be directly 
involved in controlling seizure threshold. Nonetheless, the findings described 
herein support the further evaluation of BGT1 as a potential therapeutic target for 
a number of neurological disorders including depression, anxiety, and other 
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HIPPOCAMPAL BETAINE/GABA TRANSPORTER mRNA EXPRESSION  






GABA is the primary inhibitory neurotransmitter in the mammalian CNS, and 
after its release from interneurons, GABAergic signaling is terminated via 
reuptake by GABA transporters (Madsen et al. 2010). The betaine/GABA 
transporter (BGT1) is able to transport the organic osmolyte betaine as well as 
GABA, and is therefore both an osmolyte transporter and a GABA transporter 
(GAT). A variety of GAT alterations have been shown to exist in epilepsy. GAT1 
and GAT3 expression are altered in a time-dependent manner following seizure 
activity; GAT1 may transiently increase postseizure but is consistently 
downregulated chronically. Similarly, GAT3 has been reported to both increase 
and to decrease following seizure activity (Hirao et al. 1998; Ueda and Willmore 
2000; Andre et al. 2001; Patrylo et al. 2001; Sperk et al. 2003; Zhu and Ong 
2004a). GABA transporters display altered distribution and decreased function in 
tissue from humans with epilepsy (During et al. 1995; Mathern et al. 1999; 





expression was reported to increase post-SE (Zhu and Ong 2004a). GAT 
downregulation in epilepsy may serve to increase tonic inhibitory conductance by 
increasing the extracellular GABA concentration. However, these transporters 
are able to reverse and release GABA under certain conditions such as elevated 
extracellular K+ and glutamate (Gaspary et al. 1998; Heja et al. 2009), which is 
known to occur during seizures (Krnjevic et al. 1982; Somjen and Giacchino 
1985; Liu et al. 1997). Downregulation of these transporters, then, may 
exacerbate seizure activity because transporter reversal may be important in 
seizure cessation or in preventing seizure spread (Patrylo et al. 2001). Indeed, it 
has been shown that glutamate causes a significant increase in extracellular 
GABA in nonepileptogenic hippocampi, but not in epileptogenic hippocampi from 
patients with refractory epilepsy (During et al. 1995). However, GAT inhibition 
remains a viable anticonvulsant strategy despite seizure-related downregulation 
as demonstrated by the clinical efficacy of the specific GAT1 inhibitor, tiagabine 
(Madsen et al. 2010). The role of BGT1 in controlling neuronal excitability is 
unknown. However, it is evident that inhibition of GAT1 by tiagabine can control 
seizures and that seizures can alter the expression of GAT1 and GAT3.  
The role of osmolyte transporters in epilepsy is less clear, but several 
associations exist. Organic osmolytes accumulate in cells and cause water 
retention to avoid cell shrinkage in hyperosmotic solutions without disturbing 
cellular function (Yancey et al. 1982; Lang et al. 1998; Wehner et al. 2003; 
Strange 2004). Dehydration causes the upregulation of genes responsible for the 





(Burg et al. 1997; Waldegger and Lang 1998; Handler and Kwon 2001). Through 
this mechanism, osmolyte transporters modulate the size of the extracellular 
space (ECS) by exerting control over cell size. Excessive neuronal activity, such 
as that associated with epileptiform bursts, causes cell swelling and ECS 
reduction (Dietzel et al. 1982). A reduced ECS enhances neuronal excitability, 
while an increased ECS dampens excitability (Dudek et al. 1990; Schwartzkroin 
et al. 1998). Therefore, osmotic homeostasis is important in controlling neuronal 
excitability. In addition, seizure-induced alterations to osmotic stress have been 
described. The Na+/myo-inositol co-transporter (SMIT) is significantly increased 
post-SE (Nonaka et al. 1999). Furthermore, levels of the organic osmolyte, 
taurine, are altered by seizures (Lehmann et al. 1985; Baran 2006), and BGT1 
expression is reportedly increased following kainic acid-induced SE (Zhu and 
Ong 2004a). In addition, betaine, myo-inositol and taurine all display 
anticonvulsant activity, suggesting a direct interaction between osmotic status 
and seizure susceptibility (Freed et al. 1979; French et al. 1986; Patishi et al. 
1996; Solomonia et al. 2007; Junyent et al. 2009).  
Transcription plays an essential role in the upregulation and insertion of BGT1 
into the cell membrane. Increased transcription, rather than increased mRNA 
stability, is responsible for a significant proportion of the hypertonicity-induced 
increase in BGT1 (Uchida et al. 1993; Lammers et al. 2005) and aldose 
reductase (AR) (Garcia-Perez 1995). There is also extensive post-transcriptional 
control over the surface expression of BGT1. De novo synthesis and membrane 





BGT1 upregulation in the kidney (Basham et al. 2001; Kempson et al. 2003). In 
the absence of a specific antibody that can reliably detect BGT1 in brain tissue, 
mRNA studies remain able to produce meaningful results since de novo 
synthesis is known to contribute to BGT1 upregulation in other tissues.  
The known transcription factor for BGT1 is the tonicity-responsive enhancer 
binding protein (TonEBP). TonEBP expression increases and it is translocated to 
the nucleus in response to dehydration in the kidney (Woo et al. 2000b) to 
promote the expression of osmoprotective genes: the osmolyte transporters 
BGT1, the taurine transporter (TauT), and SMIT, as well as the intracellular 
enzyme responsible for the production of the osmolyte sorbitol, aldose reductase 
(AR) (for review see (Woo et al. 2002)). The osmoprotective genes are able to 
increase in the brain in response to hypertonicity and cause alterations in 
osmolyte tissue content (Heilig et al. 1989; Lien et al. 1990; Verbalis and Gullans 
1991; Ibsen and Strange 1996; Minami et al. 1996; Bitoun and Tappaz 2000b). 
While TonEBP is believed to be the major transcriptional regulator of the 
osmoprotective genes in the kidney and is able to perform bidirectional regulation 
of the osmoprotective genes (Burg et al. 1996; Miyakawa et al. 1999b; Woo et al. 
2000a; Na et al. 2003; Lopez-Rodriguez et al. 2004), this does not appear to be 
true in the brain. For example, TonEBP is expressed differentially from its 
downstream osmoprotective genes in the brain with regard to cell type, region, 
and expression level (Maallem et al. 2006b). Furthermore, the expression of 
TonEBP and of each osmoprotective gene varies by tissue (Zhang et al. 2003). 





in the brain (Loyher et al. 2004; Maallem et al. 2006a), yet other non-neuronal 
cells, such as astrocytes and endothelial cells, can upregulate the 
osmoprotective genes in response to osmotic stress, suggesting a TonEBP-
independent mechanism (Isaacks et al. 1994; Strange et al. 1994; Wiese et al. 
1996; Bitoun and Tappaz 2000a; Petronini et al. 2000; Maallem et al. 2006b). 
Recently, it has been suggested that an endogenous inhibitory GABAergic 
system exists within the immune system, which includes the presence of GATs 
on T cells and macrophages (Bhat et al. 2010). Furthermore, inflammation has 
been shown to modulate the expression of GATs. GAT1 and GAT3 are increased 
in the spinal trigeminal nucleus following carrageenan injection, a response likely 
to contribute to hyperalgesia (Ng and Ong 2001). Following an encephalitic 
insult, GAT1 is significantly downregulated in the spinal cord of WT mice, and the 
GAT1 KO mouse has an exacerbated response to an encephalitic insult, 
suggesting that GAT1 is an important modulator of antigen-specific T cell 
responses (Wang et al. 2008). TonEBP is also known as nuclear factor of 
activated T-cells 5 (NFAT5), an inflammatory-mediated transcription factor. 
Despite a significant increase in TonEBP in response to an inflammatory stimulus 
in T lymphocytes, AR did not increase (Trama et al. 2000). Furthermore, 
immunosuppressant drugs do not alter the hypertonicity-induced upregulation of 
BGT1, and different immunosuppressants display divergent effects regarding 
SMIT activity (Atta et al. 1999). The available data indicate that 1) TonEBP may 
regulate the osmoprotective genes only in response to osmotic stimuli, not to 





relevant in select tissues, but not in the brain. As discussed above, this 
expression pattern was compared to that of other GABA transporters as well as 
osmoprotective genes. 
The current study was performed to determine if BGT1 mRNA (SLC6a12) 
expression is altered in the hippocampus following SE, and to investigate 
whether inflammation and/or dehydration may contribute to the BGT1 response 




Animals: Adult male C57/B6 mice weighing a minimum of 18 grams (Charles 
River, Kingston, WA) were used. Animals were housed in a temperature-, 
humidity-, and light-controlled (12 h light: dark cycle) facility. Mice were group-
housed and permitted free access to food and water except during the 
dehydration protocol. All experimental procedures were performed in accordance 
with the guidelines established by the National Institutes of Health (NIH) and 
received approval from the University of Utah’s Animal Care and Use Committee 
(IACUC). 
Pilocarpine-induced status epilepticus (SE): Pilocarpine SE was induced by 
injection of 330 mg/kg (i.p.) pilocarpine hydrochloride in 0.9% saline (Mazarati et 
al. 2004) (Sigma, St. Louis, MO). -/- scopolamine methyl-bromide (1 mg/kg, 
Sigma-Aldrich, St. Louis, MO) was administered 30 min prior to pilocarpine 
injection to reduce peripheral cholinergic effects (Shibley and Smith 2002). Mice 





according to a modified Racine scale (Racine 1972), or at least one stage 5 
seizure accompanied by continuous clonus were considered to have undergone 
SE. The motor component of SE was abolished after 60 min by an injection of 
diazepam (10 mg/kg, i.p., Sigma-Aldrich, St. Louis, MO). Mice in the control 
group received 0.9% saline in place of pilocarpine; otherwise they were treated 
identically to experimental animals.  
Induction of inflammation and dehydration: mRNA levels of SE animals were 
compared to levels from animals 24 h following LPS injection (4 mg/kg, i.p., strain 
0111:B4, Sigma-Aldrich, St. Louis, MO) or after 24 h of water withdrawal (n=10 
per group). The presence of an inflammatory response was confirmed utilizing 
core body temperature and weight measurements. Body temperatures were 
determined at baseline and hly for 4 h postinjection, then again at 8 h and 24 h. 
The peak body temperature reached by each mouse was compared to its 
individual baseline temperature, and the temperature change was determined for 
each mouse in order to normalize for mice with low or high basal temperature. 
Dehydration was determined by plasma osmolality values. Blood was obtained 
from mice by decapitation and centrifuged for 3 min at >3,000 g to separate 
plasma. Plasma osmolality was determined utilizing an osmometer (Advanced 
Instruments, Inc., Model 3320 Osmometer, Norwood, MA).  
RNA extraction and cDNA synthesis: Eight, 24, and 72 h, 1 week and 4 
weeks post-SE, animals were sacrificed by cervical dislocation and hippocampi 
were dissected out for gene expression determination (n=6-9 per group). RNA 





according to the manufacturer’s instructions. A NanoDrop 3300 
Spectrophotometer (Thermo Fisher Scientific, Pittsburgh, PA) was utilized to 
calculate RNA concentrations based on spectral absorbance at 260/280 nm. A 
standard RT reaction was run to produce cDNA. Two µg of total RNA, 1 µl of 250 
ng/µl random hexamers, 1 µl of 10 mM dNTPs, and water to a volume of 13 µl 
were heated to 65 °C for 5 min. Four µl of 5x First Strand buffer, 2 µl of 0.1 M 
DTT, and 1 µl of SuperScript II (Invitrogen, Carlsbad, CA) were added and the 
reaction run at 42 °C for 50 min then 70 °C for 15 min. Fifty µl of purified water 
was added and samples stored at -20°C until use.  
Quantitative PCR: Osmolyte-related, GAT1 and GAT3 internal standards for 
PCR were cloned, while the standards and primers for BGT1 were purchased 
from Origene (Rockville, MD). The University of Utah DNA Sequencing Core 
Facility confirmed the cloned DNA sequences and a BLAST search was 
performed to confirm gene specificity. Primer sequences and product sizes are 
presented in Table 2.1. The quantitative PCR reaction contained 12.5 µl of RT2 
Real-Time SYBR Green PCR Master Mix (SA Biosciences, Frederick, MD), 10.5 
µl of purified water, 1 µl of 10 µM primer set, and 1 µl of cDNA template. 
Quantitative PCR was performed using a PTC-200 Peltier Thermal Cycler with a 
Chromo4 Continuous Fluorescence Detector (MJ Research Inc., Waltham, MA). 
Data was analyzed with MJ Opticon Monitor Analysis Software, Version 3.00 
(Bio-Rad Laboratories, Hercules, CA). All values were normalized to Proteosome 





2005). Primer sequences, annealing temperatures, and product sizes are 
presented in Table 2.1. Each gene was amplified for 35 cycles. 
Analysis and statistics: All genes were normalized to the value of the 
housekeeping gene, Psmb6, for that sample and expressed relative to a mean 
control value of 100. Results are presented as mean ± SEM. A two-tail Student’s 
t-test was utilized prior to normalization to determine significant differences 
between control and experimental groups. Differences were considered 
significant at p < 0.05.  
 
Results 
The mRNA expression levels of BGT1, GAT1, GAT3, TauT, SMIT, AR, and 
TonEBP were determined 8 h, 24h, 72h and 1 and 4 weeks following pilocarpine-
induced SE. Figure 2.1 displays the temporal expression pattern of the genes 
following SE. Eight h following SE, SMIT mRNA was increased significantly, 
while GAT1 mRNA was decreased compared to control values. At 24 h post-SE, 
BGT1 mRNA expression was significantly increased, as were the osmolyte 
transporters SMIT and TauT. GAT3 mRNA was decreased whereas GAT1 
mRNA had returned to control values. At the 72 h time-point BGT1 mRNA 
expression was significantly decreased along with GAT1 and GAT3, while SMIT 
remained increased. Hence, the expression of BGT1 switched from being similar 
to that of the osmolyte transporters early on post-SE (24 h) to being more like 
that of the GABA transporters at a later time-point (72 h). This pattern was again 
observed 4 weeks post-SE, when BGT1, GAT1, and GAT3 mRNA were 











Table 2.1: Primers for PCR amplification  
Gene Forward Primer Reverse Primer AT PS (bp) 
GAT1 taacaacaacagcccatcca ggagtaaccctgctccatga 60°C 326 
GAT3 tttggtcttccccttttcct aagactccactcaaccccct 60°C 214 
SMIT cactctgagtggatacttcc tctcttaacttcctcaaacc 52°C 544 
TauT tccacaaagacatcctgaagc ggtgaagttggcagtgctaag 60°C 539 
AR ttgactgcgcccaggtgtac tatatgctgtcaccacgatgc 60°C 504 
TonEBP atgcaatttcagaatcagcc gcatttgctgagaaagaag 60°C 514 
Psmb6 tctgatggcaggaatcat acatagccatagatgtacga 57°C 137 
 
GAT, GABA transporter; SMIT, sodium/myo-inositol cotransporter; TauT, taurine 
transporter; AR, aldose reductase; TonEBP, tonicity-responsive enhancer 
binding protein; Psmb6, proteosome subunit beta 6; AT, annealing temperature; 













Figure 2.1: Alterations in GAT (A) and osmoprotective (B) gene mRNA 
expression 8 h, 24 h, 72 h, 1 wk, and 4 wks postSE (means ± SEM). Results are 
expressed relative to control values (normalized to 100%). *= p<0.05 vs. control; 

















































































































































































affected by SE at  any of the time-points examined. The transcription factor of the 
osmolyte-related genes, TonEBP, was downregulated 72 h post-SE, and was not 
altered at other time-points. As such, there is no apparent relationship between 
the expression of the osmolyte-related genes and TonEBP post-SE. Interestingly, 
no gene investigated was different from control values one week following SE.    
BGT1 mRNA expression appears to be regulated similarly to the osmolyte 
transporters 24 h post-SE. Since osmolyte transporters may be subject to 
regulation by the systemic osmotic state, dehydration due to intense motor 
activity during SE could contribute to the observed upregulation of TauT, SMIT, 
and BGT1. Animals were significantly dehydrated following both SE and 24 h of 
water withdrawal compared to controls (p<0.01 for both groups; control = 313.3 ± 
0.99 mOsm/kg; 24 h post-SE = 326.4 ± 3.1 mOsm/kg; 24 h water withdrawal = 
327.7 ± 1.3 mOsm/kg). Plasma osmolality values between experimental groups 
were strikingly similar. Therefore, the expression profiles of these two groups 
were compared to determine the impact of dehydration on the expression 
patterns seen post-SE. As shown in Figure 2.2, SE animals experienced 
significantly greater alterations in osmoprotective genes than those observed in 
dehydrated animals. In fact, only SMIT was significantly increased following 24 h 
of water withdrawal. This is not surprising, because a mild dehydration protocol 
was chosen for this study to produce similar plasma osmolality values to those 













Figure 2.2: Effect of SE (24 h postinsult) and 24 h water withdrawal on 
osmoprotective gene mRNA expression (means ± SEM). Results are expressed 
relative to control values (normalized to 100%). BGT1, TauT, and SMIT mRNA 
are significantly higher post-SE than postdehydration. †= p<0.05; ††= p<0.01 vs. 








































transporter mRNA expression following SE are not accounted for by dehydration. 
BGT1 mRNA expression is downregulated 72 h and 4 weeks post-SE, 
similarly to the GABA transporters, GAT1 and GAT3. The effect of an 
inflammatory insult on the downregulation of these genes was investigated. LPS-
induced inflammation was confirmed by a significant increase in body 
temperature (p<0.01; control= -0.01 ± 0.07 °C; LPS= 1.21 ± 0.29 °C) and weight 
loss (p<0.01; control= -0.1 ± 0.1 g; LPS= -3.3 ± 0.1 g) compared to controls. 
Plasma osmolality was not different between groups. As shown in Figure 2.3, 
GAT1 and GAT3 mRNA expression were decreased in response to inflammation, 
while BGT1 mRNA expression was not altered. Inflammation may therefore 
contribute to the regulation of GAT1 and GAT3. As seen in Figure 2.4, BGT1, 
TauT, SMIT, and AR mRNA levels were not altered post-LPS. TonEBP, however, 
was significantly increased by exposure to LPS. These results illustrate that, 
despite being a known transcription factor of the investigated osmoprotective 
genes, TonEBP does not appear to activate these genes in response to the 
specific inflammatory stimulus utilized in this investigation.   
 
Discussion 
Osmoprotective gene expression is altered by tonicity due to promotion by the 
transcription factor TonEBP. Under osmotic stress, TonEBP expression can 
increase and alter the expression of BGT1, TauT, SMIT, and AR (Woo et al. 













Figure 2.3: Effect of SE (4 weeks postinsult) and LPS (24 h postinsult) on GAT 
mRNA expression (means ± SEM). Results are expressed relative to control 
values (normalized to 100%). GAT1 and GAT3, but not BGT1, are altered 


















































Figure 2.4: Effect of SE (24 h postinsult) and LPS (24 h postinsult) on 
osmoprotective gene mRNA expression (means ± SEM). Results are expressed 
relative vehicle controls (normalized to 100%). BGT1, TauT, and SMIT mRNA 
are altered post-SE while TonEBP is altered post-LPS. †= p<0.05; ††=0.01 vs. 


















































 expression observed in osmoprotective genes following SE were due to 
dehydration. Following SE, animals were dehydrated to a similar extent to 
animals that had water withheld for 24 h as determined by plasma osmolality 
values. However, SE produced upregulation of BGT1, TauT, and SMIT mRNA, 
while 24 h water withdrawal caused exclusive upregulation of SMIT mRNA.  
SMIT, TauT, and BGT1 mRNA values following 24 h water withdrawal were 
significantly lower than the expression values following SE. This result indicates 
that dehydration does not account for the upregulation of the osmolyte 
transporters following SE. 
BGT1 expression has been shown to closely mimic TonEBP expression in the 
kidney, but an apparent disparity exists between their expression patterns in the 
brain (Zhang et al. 2003; Maallem et al. 2006b). In agreement with these 
previously reported trends, the current study also found that osmolyte-related 
genes do not mimic TonEBP expression in the brain following SE, mild 
dehydration, or inflammation. While SMIT, TauT, and BGT1 mRNA were 
increased 24 h post-SE, TonEBP mRNA was unaltered at this time-point. 
TonEBP and BGT1 mRNA were significantly downregulated at 72 h post-SE, 
while SMIT was upregulated and TauT was not different from control values. At 4 
weeks post-SE, SMIT was increased and BGT1 was decreased, while TonEBP 
and TauT were not different from controls. Thus, it appears that the mRNA 
expression patterns of the osmoprotective genes are not following those of 
TonEBP in the brain. Furthermore, they also appear to be regulated differentially 





manipulation performed in the current study, i.e., SE, mild dehydration, or 
inflammation. This is not surprising because of the determined discrepancy 
between expression of these genes in the brain, and because a mild dehydration 
protocol was utilized. From the currently available data, it appears that the 
osmolyte transporters are not exclusively regulated by TonEBP in the brain.  
Inflammation was thought to contribute to the alterations in GATs and 
osmoprotective genes because both GAT1 (Wang et al. 2008) and TonEBP 
(Trama et al. 2000) have been previously associated with inflammation. 
Furthermore, seizures induce rapid yet persistent CNS inflammation which can 
enhance neuronal excitability, reduce cell survival, and increase blood-brain 
barrier permeability, resulting in a predisposition to seizure activity (see (Vezzani 
and Granata 2005) and (Choi and Koh 2008) for reviews). Therefore, mRNA 
values observed post-SE were compared to those obtained from mice that had 
been subjected to an inflammatory insult to determine whether inflammation 
could contribute to the downregulation seen post-SE. GAT1 and GAT3 values 
were decreased post-LPS compared to controls, and were not significantly 
different from SE animals. This finding supports the hypothesis that inflammation 
may contribute to GAT downregulation post-SE; however, it appears that GAT 
downregulation post-SE is more severe than post-LPS, suggesting that other 
mechanisms contribute to the observed post-SE GAT downregulation. Further 
studies will be necessary to determine the nature and extent of inflammation 
post-SE, and to determine the degree to which inflammation may actually 





TonEBP (NFAT5) is induced by T-cell activation, but AR is not increased by 
this receptor-mediated stimulus (Trama et al. 2000). The current study 
complements these data, and is the first to investigate inflammatory-mediated 
regulation of TonEBP in the brain, as well as its downstream targets. The results 
demonstrate that TonEBP is responsive to neuroinflammation but does not 
regulate osmotic elements under the specific conditions investigated. BGT1, 
TauT, and SMIT were significantly altered post-SE, but were not changed post-
LPS. Hence, inflammation does not contribute to the transcriptional response of 
BGT1 and the osmolyte transporters under the investigated conditions. 
Surprisingly, TonEBP was not upregulated following SE, despite the known 
occurrence of an inflammatory response following seizures. It is possible that 
TonEBP is regulated by only a subset of inflammatory stimuli, e.g., TonEBP 
responded to LPS, which signals through Toll-like receptor 4 (Poltorak et al. 
1998). The innate and/or adaptive inflammatory mediation following seizures may 
not activate pathway(s) that activate TonEBP expression, although Toll-like 
receptor 4 has been implicated in ictogenesis (Maroso et al. 2010).    
The observed expression patterns closely mirror the phases of the 
pilocarpine-induced SE model of temporal lobe epilepsy. This model includes an 
acute insult that produces seizure activity, followed by a recovery period during 
which animals have a low probability of seizures (Williams et al. 2007), followed 
by a chronic period when spontaneous seizure activity occurs (Leite et al. 2002). 
The phase of low seizure probability is referred to as the latent period, and is the 





eventual development of spontaneous seizures, i.e., epileptogenesis (Loscher 
1998; White 2002). Approximately 2 weeks following SE (13.1 ± 2.4 d in C57/B6 
mice, (Shibley and Smith 2002)), animals begin to display recurrent spontaneous 
seizure activity, although monitoring was not performed in the current study. The 
observed genes were altered in the acute and long-term phases of the model, 
but returned to normal during the latent period. The functional significance of the 
current findings remains to be determined. Since GATs are able to reverse and 
release GABA into the extracellular environment (Attwell et al. 1993; Levi and 
Raiteri 1993), the net effect of their upregulation is unclear. 
The results obtained in this investigation are similar to previous studies. SMIT 
was increased following kainic acid-induced SE, and peaked in CA1 of the 
hippocampus at 24 h post-SE before returning to normal (Nonaka et al. 1999). 
The study was only carried out for 1 week, so a long-term comparison cannot be 
made with this study. Kainic acid-induced SE also caused a downregulation of 
GAT1 and GAT3 mRNA. GAT1 was significantly downregulated at 24 h and 30 d 
post-SE, but returned to normal at 1-week post-SE. These results are in close 
agreement with those found in the current study. GAT3, however, remained 
consistently downregulated following kainic acid-induced SE, in contrast to the 
results obtained with pilocarpine-induced SE in this study (Sperk et al. 2003). As 
such, it is important to keep in mind that different results may be observed in 






In summary, BGT1 mRNA expression is upregulated early post-SE along with 
other osmolyte transporters; at later time-points, BGT1 is downregulated along 
with the GABA transporters. TonEBP does not appear to exert full control over 
the expression of BGT1 and the other osmoprotective genes in the brain, nor 
does it induce their expression in response to acute LPS-induced inflammation. 
Neither plasma osmolality nor inflammation appear to account for the changes 
observed in BGT1/osmolyte transporter mRNA expression post-SE. In contrast, 
inflammation may contribute to the downregulation of GAT1 and GAT3. The 
mediator(s) of BGT1/osmoprotective mRNA regulation in the brain post-SE 
therefore remain(s) unknown. However, it is evident that these genes are altered 
by seizure activity. Since osmotic balance plays a role in controlling neuronal 
excitability, further investigation into the regulation of, and the role played by 
these genes in epilepsy is warranted. BGT1 is of particular interest due to its 
ability to transport both GABA and the organic osmolyte betaine.  
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Summary Chronic electrical stimulation via corneal electrodes can rapidly yield large num-
bers of kindled mice with a seizure phenotype reﬂective of secondarily generalized partial
seizures. The corneal kindled mouse model has been found to be a highly sensitive and efﬁcient
screening model for antiepileptic drug (AED) discovery. The present study further evaluates the
utility of the corneal kindled mouse model as a tool for rapid screening of investigational AEDs.
Results obtained with nine AEDs (valproic acid, lamotrigine, phenytoin, carbamazepine, leve-
tiracetam, vigabatrin, topiramate, tiagabine, and ezogabine) with varying mechanisms of action
and clinical spectrums, as well as six investigational compounds were evaluated in the corneal
kindled mouse. ED50 values are compared to those obtained in the hippocampal kindled rat,
the mouse maximal electroshock (MES) model, the 6 Hz partial psychomotor seizure model, and
the subcutaneous pentylenetetrazol (scPTZ) test. The results obtained in the corneal kindled
mouse demonstrate a positive correlation with those attained employing established preclini-
cal models: MES (r2 = 0.9511), scPTZ (r2 = 0.9697), 6 Hz (r2 = 0.9519), and hippocampal kindling
(r2 = 0.9037). The demonstrated predictive ability of the corneal kindled mouse model supports
its use in the early evaluation of investigational AEDs.
© 2010 Published by Elsevier B.V.
Introduction
There are a number of animal models of evoked seizures
and epilepsy currently employed in the search for new
antiseizure drugs; however, no one model can successfully
* Corresponding author. Fax: +1 801 581 4049.
E-mail address: swhite@hsc.utah.edu (H.S. White).
predict efﬁcacy for every new AED. For this reason, a
diverse set of preclinical models is incorporated in the ini-
tial screening of candidate compounds (White et al., 2002).
The maximal electroshock (MES) seizure model, ﬁrst utilized
in 1937 (Putnam and Merritt, 1937), led to the discovery of
the anticonvulsant properties of phenytoin (PHT). Following
this discovery, the MES test became established as one of
the primary preclinical screening tools utilized in the search
for new AEDs. Other acute screening tools commonly used
0920-1211/$ — see front matter © 2010 Published by Elsevier B.V.
doi:10.1016/j.eplepsyres.2010.09.002
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include the subcutaneous pentylenetetrazol, also known as
metrazol, test (scPTZ or scMet) and the 6 Hz partial ‘psy-
chomotor’ seizure test (White et al., 2002). Unfortunately,
clinical results have challenged the predictive nature of both
the MES and the scPTZ acute seizure models. For example,
levetiracetam (LEV) was found to be inactive in the MES
and scPTZ screens. In contrast, LEV was active in the rat
amygdala kindling seizure model (Löscher et al., 1998), a
chronic model of epilepsy. LEV is currently a clinically uti-
lized AED with a novel mechanism of action; i.e., it binds
with high afﬁnity to a synaptic vesicle protein (SV2A) (Lynch
et al., 2004). The inability of the primary screens to identify
the anticonvulsant efﬁcacy of LEV raised signiﬁcant concerns
regarding their capacity to identify drugs with novel mech-
anisms of action. The MES screen also failed to detect the
efﬁcacy of tiagabine (TGB) and vigabatrin (VGB), two clini-
cally efﬁcacious AEDs that work to increase synaptic GABA
levels, albeit via different mechanisms. Furthermore, the
MES model may determine efﬁcacy that is not reproducible
in humans. For example, NMDA antagonists are very effec-
tive in the MES screen, but their efﬁcacy in human patients
with epilepsy could not be demonstrated at doses that were
devoid of psychiatric complications (Löscher and Hönack,
1991). The 6 Hz seizure test is non-discriminating at low
stimulus currents and can be used as a screen to identify
potential AEDs. As the stimulus intensity is increased, it
becomes highly discriminating and can be used to differen-
tiate an investigational drug from those currently available
for the treatment of partial epilepsy. For example, at high
stimulus intensities, PHT, carbamazepine (CBZ), lamotrigine
(LTG), and topiramate (TPM) are all inactive at non-toxic
doses. In contrast, with the exception of TPM, all of these
compounds are active at lower stimulus intensities (Barton
et al., 2001). Also, LEV is active in the 6 Hz test, while it
is inactive in the other primary screens; e.g., the MES and
scPTZ tests. Thus, the 6 Hz model is useful for differentiating
the pharmacological proﬁle of investigational compounds.
The ideal preclinical model, as described by the National
Institutes of Health (NIH)/NINDS/American Epilepsy Society
(AES) Models II Workshop (2002), (1) would display sponta-
neous seizures following an appropriate post-insult latent
period, (2) would be resistant to at least two existing AEDs,
(3) would be amenable to high throughput screening, and
(4) would reﬂect a pathophysiology and phenomology simi-
lar to human epilepsy (Stables et al., 2003). While the MES
and scPTZ screens are amenable to high throughput screen-
ing, they do not meet any of the remaining criteria. The
6 Hz model possesses a differential pharmacological proﬁle
compared to MES and scPTZ tests. In this respect it can
serve as a potential screen for pharmacoresistant epilepsy.
However, the seizures are still acutely evoked and involve
a normal animal, not an epileptic animal. The kindled rat
model of partial epilepsy is a model of chronic hyperex-
citability; however, it is not particularly amenable to high
throughput screening and animals do not routinely display
spontaneous seizures. Nonetheless, electrical kindling (focal
seizures) in rats is a commonly used chronic model for tem-
poral lobe epilepsy and is highly predictive of AEDs with
clinical efﬁcacy for partial seizures (Smith et al., 2007).
In addition, the kindled rat offers a more informative look
into the epileptic condition than do the naïve, pathologi-
cally normal animals utilized in acute primary screens. The
advantage of using ‘‘seizure experienced’’ animals is that
the pharmacology of AEDs can be altered by the epileptic
pathology (Honack and Loscher, 1995). A good example of
this is the lack of observed efﬁcacy of LEV when evaluated in
models of acute evoked seizures, such as the scPTZ and MES
models, vs. the marked efﬁcacy observed in the kindled rat
model.
The corneal kindled mouse model possesses certain
advantages as a primary screening model compared to the
hippocampal kindled rat. While possessing increased clinical
predictability, most electrical kindling models are limited
by many factors, which render them impractical as pri-
mary screens. First, a signiﬁcant amount of time is required
to prepare and care for implanted rats. Second, a great
deal of skilled labor is invested in stereotaxic surgeries,
post-operative care, and kindling. Third, the means nec-
essary to ﬁnancially support the required resources and
staff are limiting. Finally, because of the age and body
mass of the rats utilized, a large amount of compound is
required for dosing. The model therefore possesses both
time- and labor-intensive preparation requirements (elec-
trode implantation surgery and a recovery period in addition
to the time required to conduct a study in a chronic model),
and the cost of the model is high not only due to time and
labor constraints but also to the chronic housing and feed-
ing of multiple adult rats. Corneal kindling in mice has been
proposed as a cost-effective alternative model for screening
compounds for the treatment of partial epilepsy (Sangdee et
al., 1982; Matagne and Klitgaard, 1998). The optic nerve is
positioned such that the brain may be transcorneally stimu-
lated, creating a non-invasive route for rapid kindling. In
addition, the smaller animal size minimizes the feeding,
housing, and dosage requirements that limit the usefulness
of the electrically kindled rat model.
Methods
Animals
Adult male CF1 mice weighing a minimum of 18 g (Charles River,
Kingston, WA) or male Sprague—Dawley rats weighing approximately
250 g at the onset of kindling (Charles River, Raleigh, NC) were used
to determine ED50 values in each of the paradigms described. Ani-
mals were housed in a temperature-, humidity-, and light-controlled
(12 h light:dark cycle) facility. Mice were group housed and rats
housed individually and permitted free access to food and water.
All experimental procedures were performed in accordance with
the guidelines established by the National Institutes of Health (NIH)
and received approval from the University of Utah’s Animal Care
and Use Committee (IACUC).
Corneal kindling (mice)
Mice were kindled according to the optimized protocol deﬁned
by Matagne and Klitgaard (1998). Brieﬂy, mice were stimulated
twice daily with a corneal stimulation of 3 mA (60 Hz) for 3 s for
an average of 12 days. Prior to each stimulation, a drop of 0.9%
saline containing 0.5% tetracaine hydrochloride (Sigma—Aldrich, St.
Louis, MO) was applied to the cornea to ensure local anesthe-
sia and good electrical conductivity. Stimulations were delivered
4 h apart. Animals were considered kindled when they displayed
ﬁve consecutive stage ﬁve seizures according to the Racine scale
(Racine, 1972). At the completion of the kindling acquisition, mice
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were permitted at least a 10-day stimulation-free period prior to
any drug testing. Mice were stimulated once the day before drug
testing to ensure they had achieved and maintained a kindled
state.
Compound screening (corneal kindled mice)
On the day of the drug study, groups of mice (n = 8) received an
intraperitoneal (i.p.) injection of the test AED. At the previously
determined time to peak effect (TPE) for each AED, motor func-
tion was evaluated using the rotarod test (Dunham and Miya, 1957),
after which mice were immediately challenged with the corneal
kindling stimulus of 3 mA for 3 s. Mice were scored as protected
(seizure score of ≤ 3) or not protected (seizure score ≥ 4), based on
the Racine scoring system (Racine, 1972). The dose was increased
or decreased between the limits of 0 and 100% protection until suf-
ﬁcient data had been obtained to calculate the median effective
dose (ED50). A 3-day washout period was permitted between each
challenge drug dose. Results were compared to those obtained in
established preclinical screening models (MES, scPTZ, 32 mA 6 Hz,
and hippocampal kindling models).
Electrode implantation (rats)
Sprague—Dawley rats were anesthetized with a single cocktail
containing 120 mg/kg ketamine hydrochloride (100 mg/ml) and
12 mg/kg xylazine (100 mg/10 ml), administered i.p. A maintenance
dose (60 mg/kg, i.p.) was given as needed. Animals were placed
in a stereotaxic device and electrodes implanted at AP − 3.6, ML
4.9, DV − 5.0 from dura, and incisor bar +5 (Lothman et al., 1988).
Dental resin was applied, followed by Triple Antibiotic Ointment,
buprenorphine (0.02 mg/kg, s.c.) and Bicillin (60,000 units, s.c.)
before animals were returned to their cages for a 1-week post-
surgical recovery period.
Hippocampal kindling (rats)
Rats were kindled according to the protocol established by Lothman
et al. (1988). Brieﬂy, rats were stimulated with suprathreshold
trains of 200 A for 10 s at 50 Hz every 30 min for 6 h (12 stimu-
lations per day) on alternate days (4—5 stimulus days) until fully
kindled.
Drug screening (rats)
One week after reaching a fully kindled state of four or more stage
4/5 seizures, the effect of a single high dose of the test substance
administered i.p. was assessed by determining its effect on the
after discharge duration and behavioral seizure score (BSS) using
the Racine scoring system (Racine, 1972). A single group of kin-
dled rats (n = 6—8) was tested at 15, 45, 75, 105, 135, 165, and
195 min after drug administration. Results obtained at the various
time points were compared with the last control stimulus, delivered
15 min prior to drug administration, so each animal served as its
own control. Previous investigations have found that repeated hip-
pocampal stimulation of animals does not negatively alter seizure
threshold in the hippocampal kindled rat model. If protection was
observed (stage 3 seizure or less) a dose—response study was ini-
tiated. The dose was varied between 0 and 100% protection and
an ED50 was calculated. Animals were used serially, and allowed a
4—5-day washout period between experiments.
Maximal electroshock test (mice)
A drop of 0.5% tetracaine hydrochloride was placed on the eyes
when the mouse received the test compound. At the previously
determined TPE, a drop of electrolyte solution (saline) and the
electrodes were placed on the eyes. Fifty mA (60 Hz) of alternat-
ing current was delivered via corneal electrodes for 0.2 s using an
apparatus originally designed by Woodbury and Davenport (1952).
This supramaximal current is sufﬁcient to evoke a maximal tonic
extension seizure in mice. Animals not displaying a full hindlimb
tonic extension were considered protected.
Subcutaneous metrazol seizure threshold test (mice)
At the previously determined TPE for the test compound, PTZ was
injected at the CD97 (85 mg/kg, s.c.) into a loose fold of skin in
the midline of the neck. Mice were placed in Plexiglas isolation
chambers (3 × 3 × 4 ) and observed for 30 min for the presence
or absence of a clonic seizure (approximately 3—5 s episode of
clonic spasms of the fore and/or hindlimbs, jaws, or vibrissae).
Animals not displaying this phenotypic behavior were considered
protected.
6 Hz ‘‘psychomotor’’ seizure test (mice)
At the previously determined TPE, mice were challenged with a
corneal stimulation of 32 mA for 3 s (6 Hz). Mice not displaying a
seizure characterized by a minimal clonic phase followed by stereo-
typed, automatistic behaviors such as jaw chomping or vibrissae
twitching were considered protected.
Anticonvulsant drug preparation
All AEDs were suspended in 0.5% methyl cellulose (Sigma—Aldrich,
St. Louis, MO) and sonicated for 15 min prior to administration to
ensure complete dissolution or a micronized suspension. Prototype
AEDs including CBZ, LTG, PHT, and valproic acid (VPA) were pur-
chased from Sigma—Aldrich, St. Louis, MO, while LEV and VGB were
kindly provided by UCB Pharma (Braine, Belgium) and the National
Institute of Neurological Disorders and Stroke, respectively. Ezo-
gabine (EZG) was kindly provided by Valeant Pharmaceuticals, Costa
Mesa, CA. TPM was kindly provided by Johnson and Johnson Pharma-
ceutical Research and Development (Springhouse, PA), and TGB was
provided by Cephalon, Inc. (Frazer, PA). In addition, results obtained
with six investigational compounds designated A—F (NIH/NINDS
Anticonvulsant Screening Project) were included in the correlation
analyses.
ED50 determination and statistical analysis
The proportion of responders was calculated as a percent of total
animals. Seizure severity was expressed as mean± S.E.M. for each
group. The ED50 and 95% conﬁdence interval (CI) for each compound
was calculated using a log-probit analysis (Finney, 1971). Additional
doses of each AED were administered until the 95% CI was inside the
dose range evaluated. Correlations were determined utilizing linear
regression (Prism Software, Version 4.02, Graphpad, La Jolla, CA).
It should be noted that ADD compound F was excluded from the cor-
relation analyses shown in Fig. 2A and D. Compound F was tested as
an outlier by submitting the ratio of the ED50 in the corneal kindled
mouse model to the ED50 in the other tests to the Grubbs extreme
studentized deviate (ESD) test for outliers (QuickCalcs Software,
Graphpad, La Jolla, CA). Compound F was determined to be an
outlier only in the correlation between the corneal kindled mouse
model and the hippocampal kindled rat model. The point corre-
sponding to compound F is shown in all panels of Fig. 2, and is
labeled in Fig. 2A and D where it was excluded from the calculation
of the displayed r2 value. r2 values for the hippocampal kindling
and MES correlations with and without compound F included are
provided in the results section.
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Figure 1 Kindling curve. Male CF1 mice weighing at least 18 g
were corneal kindled. Kindling took on average 12 days with
twice daily stimulations of 3 mA for 3 s, delivered at least 4 h
apart. Seizures were scored according to the Racine scale. Data
points are average seizure score± S.E.M. (n = 40).
Results
In the present study, 89.5% (34/38) of mice acquired a fully
kindled state; i.e., 5 consecutive stage 5 seizures. As shown
in Fig. 1, the kindling curve plateaus at an average seizure
score of 4 after 26 stimulations due to the fact that the
latency for some mice to reach a fully kindled state was
prolonged an additional 12 days. Furthermore, at this point
many animals were fully kindled and hence not receiving
stimulations, thereby lowering the average seizure score.
Of the 38 mice that entered the study, 10.5% (4/38) never
achieved a stage 5 seizure. These animals were not utilized
for compound screening. No mortality was observed during
the kindling process, and the mortality rate throughout the
course of compound screening was 15.8% (6/38), with all
deaths unobserved during the night.
With the exception of TPM, all of the AEDs tested dis-
played a dose-dependent protection against secondarily
generalized seizures in the corneal kindled mouse model.
Overall, the rank order potency obtained with prototype
AEDs was TGB > EZG > LTG > LEV > PHT > CBZ > VGB > VPA. An
ED50 could not be calculated for TPM; a maximum of 50% pro-
tection was achievable at 58.9 mol/kg. The rank order of
potency in the corneal kindled mouse matched that reported
for the Frings model of reﬂex epilepsy, a high-throughput
screening tool (TGB > LTG≥ PHT≥ TPM > CBZ > VPA) (White et
al., 2002). Importantly, the corneal kindled mouse model
was the only model to demonstrate efﬁcacy of all tested
prototype AEDs at non-toxic doses. As shown in Table 1, PHT
was active at non-toxic doses in the corneal kindled mouse
and the MES test. ED50s for LTG, PHT, TPM, and CBZ could
not be determined in the scPTZ test due to toxicity at the
highest doses evaluated. VGB and TGB were not active in the
MES model. LEV was ineffective in both the MES and scPTZ
tests. Furthermore, LEV was not able to provide full protec-
tion in the electrical kindled rat. The corneal kindling model
identiﬁed VGB, TGB, and LEV as active compounds. TPM was
inactive in the electrical kindled rat, 6 Hz, and scPTZ seizure
models.
The rank order potency of AEDs in the hippocampal kin-
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Figure 2 Paradigm correlations. Corneal kindled mouse ED50 ( mol/kg, i.p.) results were correlated with ED50 ( mol/kg) results
from the MES (A), scPTZ (B), 6 Hz (C), and hippocampal kindled rat (D) screens. Each data point represents the ED50 of a drug in
the corneal kindled mouse model vs. its ED50 in the other seizure models. Compound F was excluded from the correlation analyses
(r2 values) shown for the MES and rat hippocampal kindling correlations. See section ED50 determination and statistical analysis for
details.
test it was TGB > LTG≥ CBZ > EZG > LEV > VPA, in the scPTZ
test it was TGB > EZG > VPA, and in the MES test it was
PHT≥ EZG≥ LTG > CBZ > TPM > VPA. The ED50 values obtained
in the various models for all compounds tested are summa-
rized in Table 1.
A strong positive correlation between the effective doses
in the corneal kindled mouse model and the hippocampal
kindled rat, MES, 6 Hz, and scPTZ screens was demonstrated.
The r2 values for these correlations were 0.9037, 0.9511,
0.9519, and 0.9697, respectively. For the hippocampal kin-
dling and MES test results, the value of ADD compound F was
excluded from the correlation coefﬁcient shown in Fig. 2,
but is plotted on the correlation graph. Had this value been
included in the correlation calculation, the r2 value would
have been 0.6546 for the hippocampal kindling model and
0.6888 for the MES model. Since VPA has a much larger value
than the other compounds, it may appear that the positive
correlations depend heavily upon the inclusion of VPA. How-
ever, in the absence of VPA, a positive correlation remains
between the corneal kindled mouse model and the other
model systems. Without VPA, the r2 values for the corre-
lations are 0.7404, 0.995, and 0.8733 for the MES, scPTZ,
and hippocampal kindled rat models, respectively. With the
removal of only VPA, the 6 Hz correlation drops to 0.2515 due
to a now poorly ﬁtting value of CBZ. Following the removal
of VPA and CBZ, the r2 value for the 6 Hz correlation is
0.8442.
Discussion
The corneal kindled mouse model quickly and easily yields
a population of chronically kindled animals available for
serial use in the initial screening of AEDs. The use of this
model is preferred as an initial screen to the electrical kin-
dled rat model in that it conserves compound, time, and
labor, thereby reducing costs. It also requires less technical
skill since no surgical expertise is required. The corneal kin-
dled mouse model is advantageous over the other primary
screens, including the 6 Hz test, the MES test, and the scPTZ
test, because it displays a pharmacological proﬁle consistent
with human partial epilepsy. Moreover, it effectively iden-
tiﬁed the anticonvulsant potential of compounds that bind
to SV2A, such as levetiracetam, brivaracetam and seleter-
acetam (Rogawski, 2006). The scPTZ and MES tests did not
detect the anticonvulsant potential of LEV, while the corneal
kindled mouse and 6 Hz models did. PHT was not fully active
in the 6 Hz and scPTZ models and VGB and TGB were not
active in the MES test. TPM was not active in the hippocam-
pal kindled rat, 6 Hz, or scPTZ seizure models. The corneal
kindled mouse model, however, was able to successfully
identify the anticonvulsant activity of PHT, VGB, TGB, and
TPM. The results obtained in this study conﬁrm and empha-
size the suggestion that reliance on acute, evoked seizures
for early preclinical testing is inadequate for fully determin-
ing the anticonvulsant potential of novel compounds.
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The results obtained in the corneal kindled mouse model
correlated well with those obtained in the hippocampal
kindled rat. Furthermore, the corneal kindled mouse was
able to detect efﬁcacy for all clinically active compounds
tested. However, the results obtained in this investigation
are not intended to suggest that it would fully replace the
electrical kindled rat model. While mice can be utilized
for long periods of time if they are routinely stimu-
lated, they have been reported to lose their kindled state
after a 4-week stimulation-free period. Furthermore, the
altered sensitivity to adverse effects also disappears after
a 27-day stimulation-free period in the corneal kindled
mouse (Potschka and Löscher, 1999). These results were
not observed in the current study because animals did not
receive long stimulation-free periods. The reported loss of
kindling and adverse effect proﬁle demonstrate that brain
alterations are not permanent in the corneal model, while
they appear to be in the electrical kindled rat. The efﬁcacy
of kindling can be manipulated by stimulus intensity, dura-
tion, and the interval between stimuli. These parameters
were previously determined and optimized (Sangdee et al.,
1982; Matagne and Klitgaard, 1998). Therefore, altering the
kindling parameters does not easily ameliorate the afore-
mentioned minor drawbacks of the model. Various mouse
strains respond differently to kindling (kindling rate, mor-
tality rate, etc., unpublished observations). In the future,
an optimal strain may be determined for the use of this
model. However, for the current study it was desirable to
utilize the same mouse strain that is utilized for the other
primary screens in order to avoid the confounding factor of
strain differences.
One distinct disadvantage of the corneal kindled mouse
model is that, unlike the electrical kindled rat, there is no
electroencephalograph (EEG) available since electrodes are
not implanted. As such, the effect of an investigational drug
on focal seizure activity can only be inferred from behavioral
seizure data. In addition, the ideal epilepsy model would
generate spontaneous behavioral seizures; while kindled
animals can develop spontaneous seizures after long peri-
ods of time in an ‘‘over-kindled’’ state (Brandt et al., 2004),
this is not a practical utilization of this particular model for
compound screening. Another possible disadvantage of the
corneal kindled mouse model is that a high mortality rate
during kindling (22.5% in males) has been reported (Potschka
and Löscher, 1999). However, in the current study there was
no mortality observed during the kindling process. In the
limited scope of this study, no compound was found to be
inactive in the corneal kindled mouse, although TPM lacked
100% protection. This fact may be viewed in a positive light,
in that it conﬁrms the broad spectrum of utility for the
corneal kindled model. However, there is a great need for
a deeper understanding of pharmacoresistant epilepsy, and,
as such, an appropriate model system must be developed.
For the corneal kindled mouse to be considered a model of
pharmacoresistant seizure activity, it would have to be resis-
tant to at least two existing AEDs. Further investigation is
necessary to determine if the corneal kindled mouse has the
potential to be a model of pharmacoresistant epilepsy.
In summary, the corneal kindled mouse model requires
an initial investment in time to kindle a population of mice
for pharmacological testing; however, it provides a ‘‘seizure
experienced’’ circuit for drug testing and in this regard
more closely reﬂects that seen in patients with epilepsy. The
corneal kindled mouse model demonstrated strong positive
correlations with several diverse screening models, chronic
and acute, and electrical and chemical. Beyond its predic-
tive capacity, the corneal kindled mouse model conforms
to certain criteria for the ideal preclinical model described
previously: it is amenable to high throughput screening fol-
lowing the initial labor of the kindling process, and also
reﬂects characteristics of human partial epilepsy. The ﬁnd-
ings of this study suggest that the corneal kindled mouse
model of partial and secondarily generalized epilepsy is a
sensitive and valid screening model. The early demonstra-
tion of efﬁcacy of an investigational AED in the corneal
kindled mouse could provide sufﬁcient proof-of-concept in
a chronic seizure model to support more extensive studies
in the labor-intensive electrical kindled rat.
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PHARMACOLOGICAL PROFILE AND BGT1-SPECIFICITY OF HIT 8 
 
Introduction 
GABA is the main inhibitory neurotransmitter in the mammalian central 
nervous system; it is released from the presynaptic terminal and exerts its effects 
via ionotropic GABAA receptors and metabotropic GABAB receptors (Watanabe 
et al. 2002). GABAergic signaling is terminated by rapid uptake into the 
surrounding cells by GABA transporters (GATs). The GATs are members of the 
family of Na+ and Cl--dependent transporters (SLC6 gene family), and include 
SLC6a1, SLC6a12, SLC6a13, and SLC6a11, termed GAT1-4 (mice) or GAT1, 
BGT1, and GAT2 and 3 (rat and human) (Schousboe and Kanner 2002). The 
rat/human nomenclature is suggested by the HUGO Gene Nomenclature 
Committee and will be used hereafter.  
GABA is involved in the modulation of neuronal excitability to manage 
seizures, pain (Jasmin et al. 2004), and depression (Krystal et al. 2002; Kalueff 
and Nutt 2007). A specific GAT1 inhibitor, tiagabine (TGB), is Federal Drug 
Administration (FDA)-approved for the adjunctive treatment of partial epilepsy 
(Suzdak and Jansen 1995). Although not FDA-approved, TGB has been found 
useful for various types of pain (Novak et al. 2001; Solaro and Tanganelli 2004; 
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Kast 2005; Todorov et al. 2005; Landmark 2007), and the negative affect 
associated with clinical depression (Kalueff and Nutt 2007). Efficacy of TGB in 
these diverse disorders highlights the potential broad clinical utility of GAT 
inhibition in treating a variety of neurological disorders. Unfortunately, the use of 
TGB is limited by its inability to produce seizure freedom, its ability to actually 
induce seizures in some patient populations, and various side effects (Balslev et 
al. 2000; Genton et al. 2001). GAT1 is the predominant GAT in the mammalian 
brain (Jensen et al., 2003; Chen et al., 2004; Conti et al., 2004) and the utility of 
GAT1 inhibition as a therapeutic target has been thoroughly investigated due to 
the availability of potent and highly selective GAT1 inhibitors. Unfortunately, less 
is known about the therapeutic potential of inhibitors that target the other three 
GAT subtypes due to their lower expression levels and the lack of selective 
pharmacological inhibitors. Recently, EF1502, a compound that displays equal 
potency at GAT1 and BGT1, demonstrated that BGT1 inhibition may represent a 
novel anticonvulsant strategy. EF1502 was shown to be synergistic with TGB in 
the Frings mouse model of reflex epilepsy, the ivPTZ seizure threshold test, and 
in the corneal kindled CF1 mouse (White et al. 2005; Madsen et al. 2009). 
Furthermore, EF1502 was able to reduce spontaneous bursting in an in vitro 
model of epilepsy while TGB did not, suggesting that the BGT1 inhibitory action 
of EF1502 was partially responsible for this effect (Smith et al. 2008).  
GAT inhibitors have historically been developed based on the chemical 
structure of GABA or other known GAT substrates such as β-alanine and 2,4-
diaminobutyric acid. Both TGB and EF1502 were designed with GABA analogs 
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as scaffolds (nipecotic acid and exo-THPO, respectively (Krogsgaard-Larsen and 
Johnston 1975; Clausen et al. 2005, 2006)). Most synthesized GAT-targeting 
compounds have been found to be GAT1 selective, and attempts at synthesizing 
non-GAT1 inhibitors have largely led to compounds that inhibit all three of the 
other GATs (Thomsen et al. 1997; Beuming et al. 2006; Clausen et al. 2006). 
One potential explanation for the lack of selectivity is that the substrate-binding 
site is relatively well-conserved among the GATs (Beuming et al., 2006). 
Therefore, utilizing GAT substrates as scaffolds for inhibitor development may 
predispose to the identification of nonspecific inhibitors. To avoid this, the current 
study utilized Hit 8 (molecular weight =363.28), a BGT1 inhibitor that was 
identified in a diverse compound library screen. It is important to note that Hit 8 is 
not a GAT substrate or GABA analog. The reported GABA IC50 value for Hit 8 
was 39 µM at mouse BGT1 and 20 µM at human BGT1. In cells transfected with 
mouse GATs, Hit 8 displayed only minor inhibitory activity at GAT2 and GAT3 
(>200 µM) and was inactive at GAT1. In cells transfected with human GATs, Hit 
8 displayed minor inhibition of GAT2 (>100 µM) and no activity at GAT3 or GAT1. 
Hit 8 was concluded to be an allosteric, non-competitive inhibitor that is selective 
for BGT1 compared to the other GABA transporters (unpublished observations of 
Bolette Christiansen et al, manuscript in preparation). This library screening 
approach, as opposed to rational structural design, may aid in the identification of 
novel structures that are chemically unrelated to GABA and other GAT 
substrates and hence may display better GAT selectivity than attained utilizing 
structural design. 
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The current study was performed to determine if Hit 8 exerts an effect on 
several GABA-related behaviors including seizure susceptibility, pain, and 
depression. Furthermore, the BGT1 specificity of Hit 8 was further characterized 
in order to determine if BGT1 inhibition is likely to be functionally important in the 
mechanism of action of Hit 8.  
 
Methods 
Animal care: Male 129SV, C57/B6, or CF1 mice weighing 18-25 grams were 
used for this study (129 SV and C57/B6 mice from The Jackson Laboratory, Bar 
Harbor, ME; CF1 mice from Charles River, Kingston, WA). Male and female 
Frings mice weighing 18-35 grams obtained from an in-house colony at the 
University of Utah were also used. Mice were maintained in an AAALAC-
approved light, temperature, and humidity-controlled facility with free access to 
food and water. All procedures were carried out in accordance with the National 
Institutes of Health Guidelines for the Care and Use of Laboratory Animals and 
under approval from the University of Utah’s Institutional Animal Care and Use 
Committee (IACUC).  
In vivo evaluation: Hit 8 was tested for efficacy in several seizure models and 
the forced swim test, a model of depression.  
Seizure testing: The anticonvulsant profile of Hit 8 was characterized in 
C57/B6, 129SV, Frings, and CF1 mice. The MES, 6 Hz, and corneal kindling 
seizure tests were conducted in C57/B6 and 129SV mice as described in 
Chapter 3. A genetic model of reflex epilepsy was also utilized and is 
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subsequently described, i.e., the Frings audiogenic seizure-susceptible mouse. 
In addition, CF1 mice were utilized in the subcutaneous pentylenetetrazol 
(scPTZ) test as described.  
Audiogenic seizure test: The time to peak effect (TPE) for each compound 
was determined using 20 Frings mice; 4 at each of 5 time points (15, 30, 60, 120, 
and 240 min postinjection). The test compound was then administered at the 
TPE at varying doses (n=8 per dose, i.p.) until an ED50 could be obtained using a 
log-probit analysis. At the TPE, each mouse was tested for minimal motor 
impairment using the rotarod test as previously described (Dunham and Miya 
1957; White et al. 2005). Immediately after the rotarod test, individual mice were 
then placed into a round Plexiglas jar (diameter 15 cm, height 18 cm, model AS-
ZC, FET Research and Development, Salt Lake City, UT), where they were 
exposed to a sound stimulus of 11 kHz (110 decibels) for 20 sec. An animal was 
considered protected if it failed to display a full hindlimb tonic extension seizure. 
Mice were screened the day before drug testing to ensure that only responding 
animals were utilized.  
s.c.PTZ test: The s.c.PTZ test detects the ability of a test compound to raise 
the seizure threshold of an animal and, thus, protect it from exhibiting a clonic 
seizure.  At the previously determined TPE for the test substance, the dose of 
PTZ that will induce convulsions in 97% of mice (CD97, 85 mg/kg, i.p.) is injected 
into a loose fold of skin in the midline of the neck.  The animals are placed in 
isolation cages to minimize stress and observed for the next 30 min for the 
presence or absence of a seizure.  An episode of clonic spasms, approximately 3 
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to 5 sec, of the fore and/or hindlimbs, jaws, or vibrissae is taken as the endpoint. 
The test compound was administered at the TPE at varying doses (n=8 per dose, 
i.p.) until an ED50 could be obtained using a log-probit analysis. 
Formalin test: The test was performed using male C57/B6 mice as previously 
described (Murray et al. 1988; Tjolsen et al. 1992). The plantar region of the left 
hind paw of a mouse was injected with 5% formalin (20 µl with a 27 gauge 
stainless steel needle attached to a Hamilton syringe) 15 min (anticonvulsant 
TPE) following Hit 8 administration. Controls received a vehicle injection (0.5% 
methyl cellulose (MC), i.p.). Mice were acclimated in a 6” tall Plexiglas cylinder 
(4” diameter) for 15 min before receiving the formalin injection. Animals were 
observed for the first 2 min of each of nine 5-min epochs until 45 min had 
elapsed. The cumulative time spent licking in each 2-min period was recorded. 
Animals were immediately euthanized via CO2 chamber following the test. 
Forced swim test (FST): The FST was conducted in male C57/B6 mice as 
originally described (Porsolt et al. 1977). Testing was performed at the Hit 8 
anticonvulsant TPE (i.e., 15 min). Results obtained from Hit 8 treated mice were 
compared to those obtained from vehicle-treated controls, which received a 
vehicle injection (0.5% methyl cellulose, i.p.). Mice were placed in 2000 ml glass 
beakers filled to a depth of 10 cm of clear water (24-25 °C) and allowed one 5-
min swim trial. The last 240 sec (4 min) of swimming was analyzed, as the first 
minute serves as habituation and induction of learned helplessness. A blinded 
reviewer recorded the time that was spent immobile with a stopwatch. A mouse 
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was considered immobile when it performed only enough movement to prevent 
submersion.  
BGT1 specificity of Hit 8: Receptor binding profiles and Ki determinations for 
Hit 8 were generously provided by the National Institute of Mental Health's 
Psychoactive Drug Screening Program, Contract # HHSN-271-2008-00025-C 
(NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the 
University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at 
NIMH, Bethesda MD, USA. For experimental details please refer to the PDSP 
web site http://pdsp.med.unc.edu/ and click on "Binding Assay" on the menu bar. 
Experiments were performed in quadruplicate.  
Drug preparation: Hit 8 and TGB were suspended in 0.5% methyl cellulose 
(MC) (Sigma-Aldrich, St. Louis, MO) and sonicated for 15 minutes prior to 
administration to ensure complete dissolution or a micronized suspension. TGB 
was provided by Cephalon, Inc. (Frazer, PA), and Hit 8 was kindly provided by 
the laboratory of Rasmus P. Clausen, University of Copenhagen.  
Statistical analysis: The anticonvulsant ED50 and 95% confidence interval (CI) 
for each compound was calculated using a log-probit analysis (Finney 1971a). 
Additional doses of each AED were administered until the 95% CI was inside the 
dose range evaluated, with a minimum of four doses administered.  Formalin and 
FST data are presented as means + SEM. For the formalin test, mean area 
under the licking vs. time curve (AUC) was calculated for each group (GraphPad 
Prism, version 4.02 for Windows, GraphPad Software, San Diego, CA). A 
Student’s t-test was used to determine significant differences between groups in 
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the formalin test and FST. For all statistical comparisons, p<0.05 was considered 
significant.   
 
Results 
Anticonvulsant profile of Hit 8: The results obtained from a battery of well-
defined seizure models using Hit 8 (15 min TPE) and TGB (1 h TPE) are 
summarized in Table 4.1. As shown in this table, Hit 8 displayed an 
anticonvulsant profile distinct from that of TGB. Both compounds were efficacious 
anticonvulsants at nontoxic doses in the Frings and corneal kindled mouse 
models. In contrast to TGB, Hit 8 was active in the MES model, whereas TGB 
was active in the 6 Hz and scPTZ models while Hit 8 was not (Table 4.1). These 
differential pharmacological profiles suggest that Hit 8 and TGB are working by 
different mechanisms of action (BGT1 and GAT1 inhibition, respectively).  
Formalin test: Hit 8 was nonsedating at the dose utilized for the formalin test 
(20 mg/kg i.p.). A low dose was chosen to avoid sedation, which would confound 
the results of this behavioral test. Hit 8 was able to significantly reduce the pain 
response in both the acute and inflammatory phases of the formalin (Figure 4.1). 
In the acute phase, Hit 8 reduced paw licking to 35.82 ± 4.68% of control values 
(p<0.01). In the inflammatory phase, Hit 8 reduced paw licking to 51.25 ± 6.78% 
of control values (p<0.01).  
Forced swim test: As shown in Figure 4.2, Hit 8 (30 mg/kg i.p.) significantly 








ED50 values (mg/kg, i.p.) and (95% CI) for C57/B6, 129 SV or CF1 mice in various seizure models. C57 = 
C57/B6 mice; 129 = 129SV mice; CF1 = CF1 mice; Frings = Frings audiogenic seizure susceptible mouse 
model; MES = maximal electroshock model; 6 Hz = 6 Hz seizure model at 32 mA; Kindling = corneal kindling 
model; scPTZ = subcutaneous pentylenetetrazol test. >X = no higher doses were tested due to motor toxicity. 
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Figure 4.1: Analgesic action of Hit 8 in the formalin test. The licking response to 
formalin injection in the paw was investigated at 15 min following Hit 8 
administration (20 mg/kg, i.p.). The AUC is reduced in the Hit 8-treated group 








































Figure 4.2: Hit 8 displays antidepressant activity in the FST. Animals were 
placed in a beaker of water (24-25°C) for 5 min. The last four minutes of the test 
was analyzed and the time that each animal spent immobile determined.  p<0.01, 































immobility induced by Hit 8 suggests that it may possess potential efficacy as an 
antidepressant. 
BGT1 specificity of Hit 8: Hit 8 is specific for BGT1 of the GATs. However, 
further specificity testing was desired. Hit 8 was therefore submitted to the NIMH 
PDSP. Of the 47 receptor subtypes evaluated, Hit 8 displayed significant 
inhibition (>50%) of 13 receptor subtypes at 10 µM (results summarized in Table 
4.2). These subtypes were further investigated and a Ki value determined, also 
shown in Table 4.2. The results from the NIMH PDSP reveal that Hit 8 is in fact 
not a BGT1-specific inhibitor. 
 
Discussion 
The screening of a small compound library identified Hit 8 as a possible 
selective BGT1 inhibitor. This method was utilized in order to identify an inhibitor 
that does not structurally mimic GABA, and so would be expected to bind outside 
of the relatively conserved binding pocket of the GATs and allow for the 
identification of GAT-specific inhibitors. Indeed, this screening method was able 
to successfully identify an inhibitor selective for BGT1 compared to the other 
GATs, a feat that proved difficult with structure-based approaches.   
Hit 8 was found to possess anticonvulsant activity in the Frings and corneal 
kindling models and the MES test, but was inactive in the 6 Hz and scPTZ tests. 
Like Hit 8, TGB was also active in the Frings and corneal kindling models. In 
contrast, TGB was efficacious in the 6 Hz and scPTZ tests but not the MES test. 
TGB was also active in the Frings and corneal kindling models. Based on the 
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Table 4.2: Receptor subtypes significantly inhibited by Hit 8 
Receptor subtype % inhibition Ki (nM) 
5ht1a 49.2 8659 
5ht1d 77 584 
5ht2b 93.9 368 
Alpha2C 74.1 648.7 
D1 95.3 1260 
D2 52.5 3118 
D4 96.9 55 
H1 85 560 
M1 61.3 >10000 
M3 55 >10000 
M4 58.8 7971 
M5 89.1 2886 
MOR 51.4 3428 
 
 % inhibition and Ki values (nM) for Hit 8 at receptor subtypes as assayed by the 
NIMH PDSP. 5HT, serotonin receptor subtype; alpha, adrenergic receptor 
subtype; D, dopamine receptor subtype; H, histamine receptor subtype; M, 




differential pharmacological profile of Hit 8 compared to TGB, BGT1 inhibitors 
could theoretically be used to treat different seizure types than TGB, and the 
combination of these two drugs could be clinically useful to treat a broad 
spectrum of seizure disorders. Furthermore, BGT1 inhibition may potentially 
possess a differential and possibly less concerning adverse effect profile than 
TGB. Unfortunately, Hit 8 displayed behavioral toxicity and seizures at high 
doses. Hit 8 is analgesic, evidenced by its ability to reduce the pain response in 
both the acute and chronic phases of the formalin test at a dose devoid of 
toxicity. Hit 8 was also able to increase the active time in the forced swim test of 
depression, suggesting it may have potential antidepressant utility. The 
aforementioned data support the proposed function of Hit 8, e.g., BGT1 inhibition 
is expected to increase available extracellular GABA and be anticonvulsant, 
analgesic, and antidepressant. However, it remained unclear if BGT1 inhibition 
was indeed responsible for these results.  
To address the functionality of BGT1 inhibition in the mechanism of action of 
Hit 8, the compound was screened for activity at other molecular targets. The 
primary binding results for Hit 8 indicated that it may not be BGT1 specific; Hit 8 
significantly inhibited ligand binding to 13 of 47 targets screened. Hit 8 had Ki 
values under 10 µM at 11 of these targets. The affinity of Hit 8 for these targets 
compared to the affinity for BGT1 makes them of potential relevance in the in 
vivo testing that was performed, although the brain penetration of Hit 8 is 
unknown. Of particular interest is the fact that Hit 8 inhibits targets that are known 
to modulate seizures, depression, and pain. Several serotonin knockout animal 
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studies as well as human PET imaging studies support the hypothesis that 
serotonin plays a role in epilepsy (Theodore 2003). The selective serotonin 
reuptake inhibitor fluoxetine displays anticonvulsant activity at certain doses, and 
5HT1A stimulation is anticonvulsant in several experimental models of epilepsy 
(Wada et al. 1993; Gariboldi et al. 1996; Lu and Gean 1998; Hernandez et al. 
2002). However, antagonism has also been reported to be anticonvulsant 
(Browning et al. 1997), and 5HT1A agonists have been reported to increase 
spike-wave discharges (Filakovszky et al. 1999). 5HT3 stimulation has been 
suggested to be excitatory (Wada et al. 1997). Hence, serotonin receptor 
modulation could explain the anticonvulsant action of Hit 8 as well as its 
proconvulsant activity at high doses. Activity at dopamine receptors could also 
explain this effect: D1 stimulation is proconvulsant while D2 stimulation is 
anticonvulsant (Barone et al. 1991). It would be expected that inhibition of each 
target would produce the opposite effect. The opioid (la Fougere et al. 2009), 
histamine (Tuomisto et al. 2001), and muscarinic (Dupont et al. 1999) systems 
are also involved in epilepsy. Serotonin is a known modulator of depression, 
albeit via an unknown mechanism (Young et al. 1985; Delgado et al. 1990; 
Graeff et al. 1996). Modulation of the serotonin system may be functionally 
important in Hit 8’s mechanism of action and be responsible for the results 
obtained in the FST. Hit 8 binds to subunits of serotonin receptors, mu opioid 
receptors, histamine receptors, dopamine receptors, and muscarinic receptors, 
all of which possess pain-modulating effects (Millan 2002). Therefore, many 
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targets of Hit 8 may play a role in producing the results observed in the formalin 
test.  
With the currently available data, it seems likely that BGT1 inhibition is only a 
part of Hit 8’s mechanism of action. It should be kept in mind that a lack of effect 
of BGT1 inhibition in the context of Hit 8 does not negate the possibility that a 
truly specific BGT1 inhibitor would be therapeutically useful. However, the 
inability of BGT1 to modulate neuronal excitability in the context of seizure 
control is further demonstrated in Chapter 5 by a lack of seizure phenotype in 
BGT1 KO mice. In the future, it would be of interest to administer Hit 8 to BGT1 
KO and WT animals. If Hit 8 retains its effects in BGT1 KO animals, then BGT1 
inhibition is not a major contributor to Hit 8’s mechanism of action. As discussed 
in Chapter 5, the behavioral phenotype of BGT1 KO mice suggests that BGT1 
remains a possible therapeutic target for pain and neurospsychiatric disorders, 
and the efforts to define specific BGT1-targeting compounds should therefore 
continue.  
A screening technique was used to identify a compound that was not a GAT 
substrate or GABA analog but displayed GAT inhibitory activity selective for 
BGT1, not the other GATs. Although this approach was able to identify an 
inhibitor specific for BGT1 compared to the other GATs, it unfortunately led to the 
identification of a compound with several non-GABAergic targets. A specific 
BGT1 inhibitor therefore remains to be defined, and Hit 8 may potentially provide 
a lead structure. A BGT1-specifc inhibitor will be required to evaluate the 
potential clinical utility of this class of compounds.   
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BEHAVIORAL AND IN VITRO PHENOTYPE OF MICE LACKING  




 Introduction  
The betaine/GABA transporter (BGT1) is able to transport both the organic 
osmolyte betaine and the inhibitory neurotransmitter GABA (Lopez-Corcuera et 
al. 1992). GABA is a powerful modulator of CNS excitability, and has been 
implicated in several neurological disorders including epilepsy, pain, depression, 
anxiety, and other neuropsychiatric disorders (Koran 1976; Jasmin et al. 2004; 
Kalueff and Nutt 2007). The GABA hypothesis of epilepsy states that a decrease 
in GABAergic tone creates an imbalance between excitatory and inhibitory 
neurotransmission that can result in seizure activity. It has been previously 
demonstrated that pharmacologically increasing GABA leads to decreased 
seizure activity, while decreasing GABA is proconvulsant (Sinclair 1962; De Deyn 
et al. 1990; Dalby and Mody 2001). Several GABA-modulating drugs that were 
originally marketed as anticonvulsants are becoming increasingly utilized as pain 
medications. Tiagabine (TGB), pregabalin, gabapentin, and valproic acid are all 
prescribed for different varieties of pain and possess a mechanism of action 
involving GABA modulation (Todorov et al. 2005; Landmark 2007). Clinical data 
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also indicate efficacy of several GABAergic drugs including valproic acid, 
vigabatrin, gabapentin, and TGB for the treatment of depression, anxiety, and/or 
the manic phase of neurological disorders such as bipolar disorder (Kaufman 
1998; Meldrum and Chapman 1999; Hosak and Libiger 2002; Vieta et al. 2006; 
Kalueff and Nutt 2007).  
GABAergic signaling is terminated by reuptake of GABA into cells through 
GABA transporters (GATs) including GAT1, GAT2, GAT3, and BGT1. The 
specific GAT1 inhibitor, tiagabine (TGB), is a clinically utilized anticonvulsant with 
efficacy in pain and depression (Kalueff and Nutt 2007; Landmark 2007). 
Unfortunately, TGB is unable to ubiquitously produce seizure freedom and is 
proconvulsant under certain circumstances (Trinka et al. 1999; Balslev et al. 
2000; Genton et al. 2001). Furthermore, although TGB is relatively well tolerated, 
its use is limited by pharmacokinetic factors and side effects including dizziness, 
fatigue, and confusion (Genton et al. 2001). A better-tolerated GABA uptake 
inhibitor is therefore desirable. R,S-EF1502 is a compound that has 
approximately equal affinity for GAT1 and BGT1 (Clausen et al. 2005). Co-
administration of R,S-EF1502 with TGB resulted in a synergistic anticonvulsant 
effect in the absence of enhanced toxicity (White et al. 2005; Madsen et al. 
2009). Furthermore, R,S-EF1502 decreased spontaneous interictal-like bursting 
frequency in brain slices bathed in hyperexcitable medium, while TGB failed to 
do so (Smith et al. 2008), suggesting that the BGT1 action of R,S-EF1502 is 
functional in its anticonvulsant mechanism. BGT1 inhibition may possess a 
therapeutic profile similar to TGB with a decreased incidence of side effects due 
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to differential localization, expression patterns, and affinity for GABA compared to 
GAT1. Unfortunately, there are no specific BGT1 inhibitors available to test this 
hypothesis. Therefore, a recently created BGT1 knockout mouse (Lehre et al, 
2010, unpublished) has been utilized to determine the behavioral phenotype 
created by the lack of BGT1.   
The current study was performed to determine the behavioral phenotype 
expressed by mice lacking BGT1 in order to assess whether BGT1 inhibition may 
be a useful therapeutic tool for the treatment of various CNS disorders. The 
behavioral profile of BGT1 KO mice was evaluated in a battery of animal models 
that evaluated their susceptibility to seizures, depression, anxiety, pain, and 
alterations in locomotion. Long-term potentiation (LTP) was investigated as well 
to determine the likelihood of cognitive side effects resulting from interference of 
BGT1 function. The results from this study support the further investigation of 
BGT1 modulation in neurological disorders.  
 
Methods 
Animal care: Male and female BGT1 KO and WT littermate controls (18-30 g) 
were utilized for seizure threshold studies, while only male mice were utilized for 
other behavioral testing. Animals were housed in a temperature-, humidity-, and 
light-controlled (12h light:dark cycle) facility. Mice were group-housed and 
permitted free access to food and water. All experimental procedures were 
performed in accordance with the guidelines established by the National 
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Institutes of Health (NIH) and received approval from the University of Utah’s 
Animal Care and Use Committee (IACUC). 
Breeding and genotyping of KO/WT mice:  Heterozygous mice on a mixed 
C57/B6 and 129/SV background were obtained from Dr. Niels Christian Danbolt 
at the University of Oslo, Norway. Heterozygotes were bred, yielding KO, WT, 
and heterozygous offspring. The construct for BGT1 KO mice lacking exons 3-5 
of BGT1 is shown in Figure 5.1. At the time of weaning, a tissue sample was 
obtained from each mouse and Proteinase K-digested at 65°C for 4.5 hours. 
Digestion was terminated by incubation at 80°C for 20 minutes and the samples 
were submitted to PCR. Primers utilized were: WT forward 5’-
GGTGCATGCTTAAGACTCTG-3’; KO forward 5’-TGACCTCAAG 
CTGAATCCAC-3’; and both reverse 5’-CAAGCAGATATGGGAAGGCT-3’. 
Samples were run on a 2% agarose gel until clear band differentiation was 
possible. The wildtype allele appeared as a band at 147 bp, while the knockout 
appeared as a band at 203 bp. Heterozygotes displayed both bands. For all 
subsequent experiments, WT and KO littermates were compared. 
Plasma osmolality of KO and WT mice: Blood was obtained from mice by 
decapitation and plasma separated by centrifuging for 3 min at >3,000 g. Plasma 
osmolality was determined utilizing a freezing-point depression osmometer 
(Advanced Instruments, Inc., Model 3320 Osmometer, Norwood, MA). 
Compensation in the KO mice: mRNA levels of genes that may compensate 







Figure 5.1: Generation of the BGT1-flox mice. The gene-targeting construct 
contained exon 1-7 of the BGT1 gene. A loxP sequence (blue arrow) was 
inserted into intron 2 and an EcoRV (RV) site was created at the front of the loxp 
site. A frt-PGKneo-frt-loxP cassette was inserted into intron 5 and an 
endogenous EcoRV (RV) site was deleted. The lengths of the homologous arms 
and the floxed fragment are indicated below the construct. The black arrows 
indicate the positions of the primers used for ES cell screening. The neo cassette 
was removed in the BGT1-flox mice generated from chimera x Rosa26FLP 
crossing. The genotyping primers are indicated by black arrows. After Cre 
excision the DNA encoding amino acid residues 72-193 are deleted, which 
causes the remaining sequences to be out of frame. Furthermore, the deleted 















 (GAT1 and 3), the sodium-myoinositol co-transporter (SMIT), the taurine 
transporter (TauT), aldose reductase (AR), and tonicity-responsive enhancer 
binding protein (TonEBP). RNA was extracted and processed with RNeasy 
miniprep kits (QIAGEN, Valencia, CA) according to the manufacturer’s 
instructions. A NanoDrop 3300 Spectrophotometer (Thermo Fisher Scientific, 
Pittsburgh, PA) was utilized to calculate RNA concentrations based on spectral 
absorbance at 260/280 nm. A standard RT reaction was run to produce cDNA 
using SuperScript II (Invitrogen, Carlsbad, CA). Osmolyte-related, GAT1 and 
GAT3 internal standards for PCR were cloned, while the standards and primers 
for BGT1 were purchased from Origene (Rockville, MD). The University of Utah 
DNA Sequencing Core Facility confirmed the cloned DNA sequences and a 
BLAST search was performed to confirm gene specificity. The quantitative PCR 
reaction contained 12.5 µl of RT2 Real-Time SYBR Green PCR Master Mix (SA 
Biosciences, Frederick, MD), 10.5 µl of purified water, 1 µl of 10 µM primer set, 
and 1 µl of cDNA template. Quantitative PCR was performed using a PTC-200 
Peltier Thermal Cycler with a Chromo4 Continuous Fluorescence Detector (MJ 
Research Inc., Waltham, MA). Data were analyzed with MJ Opticon Monitor 
Analysis Software, Version 3.00 (Bio-Rad Laboratories, Hercules, CA). All values 
were normalized to Proteosome subunit β 6 (Psmb6), a housekeeping gene with 
minimal variability (Rubie et al. 2005). Primer sequences, annealing 
temperatures, and product sizes are presented in Chapter 2. Each gene was 
amplified for 35 cycles. 
 
 117
Seizure threshold determination: Seizure threshold tests included acute 
electrical tests (minimal clonic, minimal tonic extension, and 6 Hz seizure 
threshold tests) and a chemical threshold test (intravenous pentylenetetrazol 
(i.v.PTZ)). In addition, the rate of corneal kindling acquisition was estimated using 
the corneal kindled mouse model of partial seizures.  All of the electrical tests 
employed transcorneal stimulation with a Woodbury-Davenport stimulator (MES 
and corneal kindling tests, Woodbury and Davenport, 1952) or a Grass 
Stimulator (6 Hz test, Grass Technologies, West Warwick, RI). Different 
stimulation protocols (described by Otto et al., 2009) were utilized to differentiate 
the effects of BGT1 knockout on limbic (6 Hz partial seizures, 6 Hz, 3 sec), 
forebrain (minimal clonic seizures, 50 Hz, 0.2 sec), and hindbrain (minimal tonic 
extension seizures, 50 Hz, 0.2 sec) seizure thresholds. The CC50 (convulsive 
current necessary to produce the desired seizure endpoint in 50% of the 
population) was determined via the staircase procedure (Finney 1971b). Groups 
of 8 mice each were subjected to various stimulus intensities until at least four 
points were established between the intensity that failed to induce the desired 
seizure type and that which induced the desired seizure in 100% of mice. 
Additional stimulations were given as needed until the 95% confidence interval 
(CI) was inside the range of stimulations tested. The rate of corneal kindling 
acquisition was estimated according to the protocol described by Matagne and 
Klitgaard (1998) and as described in Chapter 3. The number of stimulations 
necessary to reach a fully kindled state (at least 5 consecutive stage 5 seizures, 
Racine 1972) was recorded for each mouse. For the i.v.PTZ test, a 0.5% 
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heparinized PTZ solution was infused at 0.24 ml/min into a lateral tail vein of an 
unrestrained mouse. The time to first twitch and to the onset of sustained clonus 
were recorded. The time to each endpoint was converted to the amount of PTZ 
infused (mg/kg) using the formula found in the analysis section.  
Forced swim test: The test was conducted essentially as originally described 
(Porsolt et al. 1977). Mice were placed in 2000 ml beakers filled to a depth of 10 
cm of water (24-25 °C) and allowed one 5-minute swim trial. The last 240 sec (4 
min) of swimming was analyzed, as the first minute serves as habituation and 
induction of learned helplessness. A blinded reviewer recorded the immobility 
time with a stopwatch. A mouse was considered immobile when it performed only 
enough movement to prevent submersion.  
Light-dark box: Animals were placed in a locomotor detection chamber 
(AccuScan Instruments, Inc., Columbus OH) in a darkened room. Half of the 
chamber was brightly lit with an overhead lamp while the other half was a dark 
enclosure created by a black plexiglass box. Animals were placed in the lighted 
portion of the enclosure facing away from the entrance to the black box (4” x 
1.25”). Activity was monitored for 10 min (600 sec), and the total time spent in the 
dark box was utilized to evaluate anxiety-like behavior in the mice.  
Locomotion and mania tests: Animals were placed in a locomotor detection 
chamber (16.5” x 16.5” x 12”, AccuScan Instruments, Inc., Columbus OH) for 15 
min prior to recording for habituation. Animals were recorded for 30 min to 
determine their basal locomotor activity. One week later, the same mice were 
injected with chlordiazepoxide (CDZP, 6.25 mg/kg, i.p.) and d-amphetamine (d-
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AMPH, 1.25 mg/kg, i.p.) in an attempt to induce mania. Mice were recorded at 
the time-to-peak-effect (TPE) of CDZP and d-AMPH (30 min) following a 15 min 
habituation period. A separate group of mice were injected with lithium chloride 
(100 mg/kg, i.p.) and evaluated at the TPE (30 min) following a 15 min 
habituation period. Total distance traveled (cm) was used to evaluate the effect 
of BGT1 knockout.  
Rotarod test: Mice were tested for motor deficits using the rotarod test 
(Dunham and Miya 1957). Briefly, mice were placed on a 1” diameter rod rotating 
at a speed of 6 revolutions/min. Inability to maintain equilibrium on the rotating 
rod was assessed. Latency to the first fall as well as total falls in 240 sec were 
recorded. 
Tail-flick test: The tail-flick test was performed essentially as originally 
described (D'Amour and Smith 1941) with modifications using a tail-flick 
apparatus/analgesic meter (IITC Model 336 Plantar/Tail Analgesic Meter with 
True tail Temp and Heated Glass, IITC Life Science Inc., Woodland Hills, CA). 
The cutoff latency was set at 25 sec to avoid tissue damage. Mice were 
habituated to the restraining device for 3 min approximately 4 hours prior to the 
time of the test, and again for 1 min immediately prior to the test.  
Writhing test: Acetic acid (0.6% v/v and 1.2% v/v, 10 mg/kg) was injected into 
the peritoneal cavities of mice. Mice were immediately observed for 30 min in 
observation chambers and the number of writhes counted (Collier et al. 1968). 
Writhing is characterized by the contraction of abdominal muscles with 
concurrent hind limb stretching. Animals were subsequently euthanized with CO2.  
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Formalin test: The formalin test was performed as described previously 
(Murray et al. 1988; Tjolsen et al. 1992). Corneal kindled mice were acclimated in 
a 6” tall Plexiglas cylinder (4” diameter) for 15 min before receiving a 5 % 
formalin injection (20 µl with a 27 gauge stainless steel needle attached to a 
Hamilton syringe) in the plantar region of the left hind paw. Animals were 
observed for the first 2 min of nine 5-min epochs until 45 min had elapsed. The 
cumulative time spent licking in each 2-min period was recorded. Kindled mice 
were utilized due to the unavailability of naïve WT and KO males. Animals were 
subsequently euthanized with CO2. 
Carrageenan-induced thermal hyperalgesia: A state of localized inflammation 
was induced in mice by injecting carrageenan (25 µl, 2% in 0.9% NaCl, λ-
carrageenan, Sigma-Aldrich, St. Louise, MO) subcutaneously into the plantar 
surface of the right hind paw (Kerr et al. 2001; Gonzalez-Rodriguez et al. 2010). 
Paw withdrawal responses from thermal stimulation were assessed according to 
previously described methods (Hargreaves et al. 1988; Dirig et al. 1997; Hua et 
al. 2005). Mice were placed in plexiglass chambers on top of a heated glass 
surface maintained electronically at a constant temperature (here, 30 °C). 
Thermal stimulation was applied with a projection bulb below the glass surface. 
Latency to paw withdrawal was measured from the onset of heat application until 
a full paw withdrawal occurred. After a habituation period, baseline withdrawal 
latencies were assessed at -30 min.  Carrageenan was injected at time 0, and 
withdrawal latencies were thereafter assessed every 30 min (30-210 min). At 
each time point, measurements were taken from each paw (injected, ipsilateral 
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and non-injected, contralateral), with at least 1 min between measurements. Two 
measurements were obtained from each paw and subsequently averaged to 
obtain the mean withdrawal latency for each paw at each time point.  
Experimental conditions, including animal habituation, glass plate temperature, 
and thermal stimulus intensity have been optimized such that baseline 
withdrawal latencies for contralateral and ipsilateral paws were 6-9 sec and 2-4 
sec, respectively (Dr. Cameron Metcalf, unpublished data). After the final time 
point tested, paw edema was measured using a caliper. Animals were 
subsequently euthanized with CO2. 
Hippocampal brain slice preparation: The preparation of brain slices and LTP 
experiments were designed, conducted, and analyzed by Dr. Peter West. Male 
BGT1 WT and KO mice were sacrificed by decapitation and brains were rapidly 
removed and placed in ice cold (4°C) oxygenated artificial cerebral spinal fluid 
(ACSF) (95% O2/5% CO2) containing (in mM): NaCl (126.0), KCl (3.0), Na2PO4 
(1.4), MgSO4 (1.0), NaHCO3 (26.0), glucose (10.0), and CaCl2 (2.5) – pH (7.25-
7.35) and osmolality (290-300 mOsm). Brains were then blocked and glued to 
the stage of a vibrating blade microtome (VT1000S, Leica Microsystems, Inc., 
Bannockburn, IL). Coronal brain slices (400 µm) containing the dorsal 
hippocampus were cut and then incubated in oxygenated ACSF at room 
temperature for 1-2 h prior to recording. The oxygenated ACSF used for this 
procedure is the same as that used for slice incubation and recording, and the 
pH and osmolality of this solution were verified prior to each experiment.  
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LTP at the Schaffer collateral-commissural projection to CA1 pyramidal 
neurons: Extracellular field potentials were recorded using a Slicemaster high 
throughput semiautomated brain slice recording system (Scientifica, UK). This 
system permits concurrent and independent recordings from four to eight brain 
slices, thus improving throughput, statistical design, and reducing animal use 
(Stopps et al. 2004). Slices were transferred to the integrated brain slice 
chambers (IBSCs) of this system, were held in place between two nylon nets, 
and were continuously perfused with oxygenated ACSF at a flow rate of 2.5 
mL/min. Recordings were performed at 30-31°C. Field potentials from four 
independent brain slices were recorded simultaneously. The total n represents 
brain slices from animals of each genotype. 
Concentric bipolar stimulating electrodes (MCE-100, Rhodes Medical 
Instruments, Summerland, CA) were placed in the stratum radiatum of CA1 in 
order to stimulate the Schaffer collateral-commissural axons and evoke field 
excitatory post-synaptic potentials (fEPSPs). Recording microelectrodes pulled 
from borosilicate glass (1.5 mm O.D., 1.12 mm I.D) using a PIP5 pipette puller 
(HEKA, Bellmore, NY) were filled with ACSF and placed within 300-500 µm of 
the stimulating electrodes in the stratum radiatum of CA1. Data were acquired 
using custom software written in Spike2 (CED, Cambridge, England) at a 
sampling rate of 10 kHz and low-pass filtered at 1 kHz. One hundred µs stimuli 
ranging from 5-50 V were used to evoke fEPSPs, and the magnitude of the 
fEPSP was determined by measuring the 20-80% slope of the rising phase. 
Input-output curves were generated for all slices and the baseline stimulation 
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strength was set to 50% of the range between the minimum and maximum 
fEPSP. Slices were stimulated every 30 s for 30 min at which point the degree of 
LTP was determined relative to baseline. 
Analysis:  Data are presented as means + standard error.  For the i.v.PTZ 
test, the amount of PTZ infused (mg/kg) was calculated using the formula: (19.95 
x infusion time (sec) (T)) / weight of animal in grams (W). This formula is derived 
from the calculation of mg/kg PTZ = (T x rate of infusion (ml/min) x mg PTZ/ml x 
1000g) / (60 sec x W in grams) = (T x 0.2394 x 5 x 1000) / 60 x W = (19.95 x T) / 
W. For mRNA compensation studies, the copy number of a specific gene in a 
sample was normalized to the value of the housekeeping gene, Psmb6, for that 
sample. Results are expressed relative to a mean control value of 100%, i.e., 
each experimental group was normalized to a mean control value of 100% by 
dividing each experimental value by the average control value. For the 
carrageenan test, mean withdrawal latencies for contralateral and ipsilateral 
paws were plotted separately for each group (WT and KO) as a function of time. 
Comparisons between multiple means were performed using a one-way 
repeated measures ANOVA followed by Tukey’s multiple comparisons test.  For 
the formalin test, mean area under the licking v. time curve was calculated for 
each group. For LTP experiments, data were excluded if any of the following 
were observed: erratic changes in the slope of fEPSPs during the 30 min 
baseline recording, lack of a clear and concise increase in the slope of the fEPSP 
immediately after TBS (no post-tetanic potentiation), or any sudden erratic 
changes in the slope of the fEPSP post-TBS. Unless otherwise mentioned, a 
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two-tailed Student’s t-test was used to determine if significant differences existed 
between KO and WT groups. P<0.05 was considered significant.   
 
Results 
Seizure threshold determination: Seizure thresholds were not different 
between WT and KO animals in the minimal clonic, 6 Hz, or minimal tonic 
extension tests, or in the i.v.PTZ threshold test. CC50 values (95% CI) for 
electrical tests and dose (mg/kg) of PTZ required to induce sustained clonus 
(means ± SEM) are shown in Table 5.1. 
Compensation in KO mice: mRNA levels of genes that may compensate for 
BGT1 deletion were investigated, including GAT1 and 3, SMIT, TauT, AR, and 
TonEBP. None of the investigated genes were upregulated to compensate for 
the deletion of BGT1 (data not shown).  
Plasma osmolality of KO and WT animals: Resting plasma osmolality values 
were determined to be 308.2 ± 1.7 mOsm/kg for WT mice (n=9) and 308.9 ± 1.3 
mOsm/kg for KO mice (n=8). No differences in plasma osmolality existed 
between genotypes.   
Porsolt forced swim test (FST): BGT1 KO animals (n=10) spent significantly 
greater time immobile than WT animals (n=8), shown in Figure 5.2. Therefore, 
KO mice appear to demonstrate a depressive-like phenotype in the FST.  
Light-dark box: WT and KO mice (n=9 per group) were tested for anxiety 







Table 5.1: Seizure thresholds of BGT1 WT and KO mice (mA or mg/kg)  
 
 WT KO 
Minimal clonic (mA) 8.6 (7.8-9.6) 9.0 (8.2-9.7) 
6 Hz (mA) 30.4 (26.2-33.8) 31.2 (27.1-34.8) 
Minimal tonic extension (mA) 13.1 (11.7-14.3) 13.7 (12.7-14.5) 
i.v.PTZ (mg/kg to clonus) 44.5 ± 3.0 42.3 ± 1.5  
 
Electrical seizure thresholds (minimal clonic, 6 Hz, and minimal tonic extension) 
were determined for WT and KO mice using the staircase method. CC50 values 
and (95% CI) are shown in milliamps (mA). Seizure threshold was also 
determined using the i.v.PTZ test. The dose (mg/kg, i.v.) of PTZ required to 
produce sustained clonus is reported (mean ± SEM). No differences exist 










Figure 5.2: BGT1 KO mice display a depressive-like phenotype in the FST. 
BGT1 WT (n=8) and KO mice (n=10) were tested using the Porsolt FST. KO 
mice spent more time immobile (means ± SEM) compared to WT mice in a 240 






































Figure 5.3: BGT1 KO mice display an anxiety-like phenotype in the light-dark 
box. BGT1 WT and KO mice (n=9 per group) were tested for anxiety-like 
behavior using the light-dark box. KO mice spent more time in the dark portion of 




























greater amount of time in the dark portion of the box compared to WT mice.  The 
results of this test suggest that BGT1 KO mice possess an anxiety-like 
phenotype in the light-dark box. 
Locomotor profile following CDZP/dAMPH and lithium injection: As shown in 
Figure 5.4, BGT1 KO mice (n=16) have significantly increased basal locomotor 
activity compared to WT mice (n=15). However, hyperlocomotion was not 
increased further in the KO mice with CDZP/dAMPH administration (n=13). In 
contrast, this treatment significantly increased activity in WT mice (n=11). 
Administration of lithium (100 mg/kg) attenuated basal locomotion in KO mice, 
but not WT mice (n=8 per group). WT and KO mice traveled a similar distance 
following lithium administration. Hence, the BGT1 KO mouse has increased 
basal locomotion that is not increased by CDZP/dAMPH, but that is attenuated 
by lithium at a dose that has no effect on the basal locomotion of WT animals.  
Rotarod test: BGT1 KO mice did not display motor impairment in the rotarod 
test (p=0.33, n=8 per group). No WT mice fell during the 4 min rotarod trial, and 
one KO mouse fell a single time at 21 sec.  
Tail-flick test: No difference existed in the latency to tail flick between WT 
(2.37 ± 0.29 sec, n=11) and KO (2.33 ± 0.31 sec, n=9) mice (data not shown).  
Writhing test: No difference was determined between WT (32.9 ± 3.6, n=11) 
and KO (37.2 ± 5.8, n=9) mice in number of writhes in 30 min induced by 0.6% 
acetic acid injection. Increasing the acetic acid concentration to 1.2% did not 
produce a difference between genotypes; WT (47.6 ± 6.1, n=10) and KO (53.9 ± 










Figure 5.4: BGT1 KO mice have high basal locomotion that is attenuated by 
lithium. Locomotion was determined in BGT1 WT and KO mice and expressed as 
total distance traveled (cm) in 30 minutes. Locomotion was significantly 
increased by CDZP/dAMPH injection (6.25 and 1.25 mg/kg, i.p., respectively) in 
WT but not KO mice. Basal locomotion was attenuated by lithium chloride (100 
mg/kg, i.p.) in only KO mice. * p<0.05 v WT basal; **p<0.01 v WT basal; 














































Formalin test: As shown in Figure 5.5, BGT1 KO mice had a significantly 
decreased area under the curve (AUC) in the inflammatory phase (phase II) of 
the biphasic licking response test compared to WT mice (n=8 per group), 
suggesting an attenuated response to inflammatory pain. No significant 
differences were observed in the acute phase of the response (phase I).  
Carrageenan test: As shown in Figure 5.6, there was no difference between 
genotype in carrageenan-induced thermal hyperalgesia. KO and WT groups 
exhibited significant hyperalgesia in the carrageenan-injected paw (n=8 per 
group, p<0.05), and displayed similar paw edema (KO, 2.8 ± 1.9 mm; WT, 2.7 ± 
2.0 mm). 
Long-term potentiation (LTP): As shown in Figure 5.7, there was no difference 
in LTP between BGT1 WT and KO mice. Although this result does not support 
the development of a BGT1 inhibitor for cognitive enhancement, it does provide 
evidence that BGT1 inhibition may likely be devoid of cognitive side effects.   
 
Discussion 
It was expected that BGT1 KO mice would have more available extracellular 
GABA and hence have an increased seizure threshold. However, no difference 
was observed in several different seizure threshold tests between genotypes, in 
agreement with what has previously been reported (Lehre et al. 2010, 
unpublished). However, in contrast with previous reports, there was a trend 
toward a difference in the time required to reach a fully kindled state in the 









Figure 5.5: Corneal kindled BGT1 KO mice display an analgesic phenotype in 
the formalin test. Time spent licking the paw was determined following formalin 
injection. Results are represented as (mean ± SEM) and significance determined 
by a Student’s t-test of total AUC. The time spent licking the injected paw was 







































Figure 5.6: BGT1 WT (A) and KO (B) mice exhibit a similar response to 
carrageenan-induced thermal hyperalgesia (ipsi/contra p>0.05). Latency (sec) to 
paw withdrawal was determined at several time-points following carrageenan 
injection. Both WT and KO mice withdrew the injected (ipsi) paw significantly 
faster than the non-injected (contra) paw (p<0.05, one-way repeated measures 
ANOVA with Tukey’s multiple comparison’s test). Results are represented as 




















































Figure 5.7:  LTP of excitatory synaptic transmission in the CA1 field of the 
hippocampus is normal in BGT1 KO mice.  Representative traces of fEPSPs 
from hippocampal brain slices prepared from both WT and BGT1 KO mice are 
the average of 10 sweeps taken immediately before (1, gray) or 30 min after (2, 
black) TBS.  Scale bars represent 0.25 mV and 5 msec.  Lower panel: Single 
stimuli were given every 30 sec.  fEPSP slope measurements made from either 
WT slices (○, N=20) or BGT1 KO slices (●, N=21) are represented as mean ± 
SEM.  TBS (indicated by the arrow) induces a long lasting increase in the slope 












only long-term model utilized in the present investigation, and epilepsy is a 
chronic disease. It is possible that deletion of BGT1 activity has no effect on 
acute seizure threshold, but rather modulates the condition in a chronic capacity 
by modifying long-term inhibitory tone. BGT1 expression is altered in a model of 
epilepsy (Rowley et al. submitted, see Chapter 2), which supports the idea of 
chronic involvement of BGT1 in this neurological disorder.  
One possible explanation for the lack of effect on seizure threshold is that 
developmental compensation may exist in the KOs. In the present study, other 
transporters (GAT1, GAT3, TauT, SMIT), a metabolic enzyme (AR), and a 
transcription factor (TonEBP) of interest were investigated and no compensation 
for BGT1 knockout was found. However, other compensatory mechanisms that 
were not investigated may be present. For example, GAT3 is not upregulated in 
the GAT1 KO mouse; however, GAD65/67 is increased in the cerebral cortex 
(Bragina et al. 2008), perhaps to enhance GABA synthesis to overcome the lack 
of re-uptake. Alterations in release characteristics and GABAB receptors have 
also been shown in GAT1 KO mice (Jensen et al. 2003; Xu et al. 2007). 
The animals utilized in the current studies are conventional KOs and lack 
BGT1 in all tissues. Since BGT1 has a function to regulate osmotic balance in 
the liver and kidney, plasma osmolality of KO and WT animals was determined to 
ensure no systemic osmotic differences existed between genotype. Plasma 
osmolality is important because osmotic balance contributes to neuronal 
excitability (Schwartzkroin et al. 1998). However, no difference between 
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genotypes was observed regarding plasma osmolality, in agreement with the lack 
of notable hyperexcitability in acute seizure tests.  
It has been suggested that BGT1 may not function to remove presynaptically 
released GABA due to its expression levels, localization, and affinity (Borden 
1996; Zhu and Ong 2004). The current study provides in vivo evidence that 
BGT1 is not likely to be functionally responsible for controlling neuronal 
excitability in the context of seizure thresholds.  Therefore, BGT1 is likely serving 
a function not involving the removal of presynaptically released GABA. BGT1 
transports the osmolyte betaine in addition to GABA (Lopez-Corcuera et al. 
1992). Osmotic regulation is an important aspect of brain homeostasis, and the 
ability to regulate osmolyte balance may confer functional significance to BGT1. 
In addition, it has been reported that BGT1 is the only GABA transporter present 
at the BBB (Takanaga et al. 2001), and that GABA is actively transported from 
the brain interstitial fluid to the blood through the BBB (Zhang et al. 1999; Kakee 
et al. 2001). Hence, BGT1 is the most likely candidate for mediating the efflux of 
GABA from the brain. BBB efflux does not impart an unprecedented function, and 
may pertain to betaine as well, because excitatory acidic amino acids and the 
osmolyte taurine are also effluxed across the BBB (Tamai et al. 1995; Hosoya et 
al. 1999). Another possible function for BGT1 is the redistribution of GABA from 
GABAergic to glutamatergic neurons (Sunol et al. 2010). Furthermore, BGT1 
may function to redistribute betaine following osmotic stress, as has been shown 
to occur with taurine (Nagelhus et al. 1993). Since neurotransmitter transport is 
coupled to the influx of ions, a small current is generated upon uptake. However, 
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a much larger current can be generated via cation transport through GAT1, which 
is mediated by the activation of protein kinase A. This GAT1 current is generated 
without an increase in extracellular GABA, and suggests an additional function of 
GAT1 as a “neurotransmitter-gated ion channel” (Bagley et al. 2005). The 
excitatory amino acid transporters EAAT4 and EAAT5 are also known to function 
in a similar manner under certain conditions (Fairman et al. 1995; Arriza et al. 
1997; Wersinger et al. 2006).  Hence, several potential functions of BGT1 in the 
CNS remain to be investigated. 
The BGT1 KO mouse displayed increased immobility in the FST and 
increased time spent in the dark portion of the light-dark box compared to WT 
animals. The result in the FST was not due to general hypoactivity of KO mice. 
On the contrary, BGT1 KO mice demonstrated significantly increased basal 
locomotor activity compared to WT mice in a locomotion detection chamber. The 
presence of a depressive-like phenotype in the FST and an anxiety-like 
phenotype in the light-dark test suggests that BGT1 may be functionally 
modulating the GABA system in the CNS, and that an inhibitor may possess 
neuropsychiatric side effects. 
The BGT1 KO mouse has significantly increased basal locomotion compared 
to WT mice. Hyperlocomotion is a standard parameter examined in studies of 
neuropsychological disorders that involve a ‘manic’ phase, such as schizophrenia 
and bipolar disorder. Interestingly, BGT1 KO mice were resistant to 
pharmacologically-induced hyperlocomotion; although their basal locomotion was 
significantly increased compared to WT, CDZP/dAMPH did not further increase 
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the distance traveled. The basal and CDZP/dAMPH-induced movement of the 
KO mouse does not represent a “ceiling effect,” as mice that were not habituated 
walked up to 21,000 cm (approximately 5 times the distance traveled by 
habituated, CDZP/dAMPH-injected mice). Encouragingly, the administration of 
lithium to BGT1 KO animals significantly reduced their locomotion at a dose that 
was ineffective at decreasing basal locomotion in WT mice. The lithium-treated 
KO group traveled a similar distance to the lithium-treated WT group, and neither 
lithium-treated group traveled a significantly different distance than the naïve WT 
group. Therefore, the hyperlocomotor response of the BGT1 KO mouse is 
completely reversed by lithium at a dose devoid of locomotor activity in WT mice. 
This dose of lithium would be expected to not alter basal locomotion, but to 
significantly attenuate dAMPH -induced locomotion (Gould et al. 2007). The lack 
of effect of 100 mg/kg lithium in WT mice and the marked response of the KOs 
may suggest that the BGT1 KO mouse represents a genetic model of mania that 
is attenuated by lithium at doses that do not affect basal locomotion. In the future, 
it will be imperative to test known antipsychotic compounds in the KO mice to 
determine if indeed the BGT1 KO mouse produces results that are predictive of 
clinical efficacy. Taken altogether, the increased immobility observed in the 
Porsolt FST, the basal hyperlocomotion in the activity monitor, and the clear 
reduction in basal hyperlocomotion in response to LiCl administration would 
suggest that the BGT1 KO may represent a genetic model of bipolar disorder.  
This hypothesis may warrant further investigation.  
 144
Due to the increased immobility in the FST, the increased time in the dark 
portion of the light-dark box, and increased basal locomotion of the BGT1 KO 
mouse, it may be hypothesized that inhibition of BGT1 would produce unwanted 
side effects. The current study suggests that the development of a BGT1 agonist 
may be beneficial in neuropsychiatric disorders as opposed to an inhibitor. Since 
all of the preclinical models evaluated suggest that BGT1 does not directly affect 
seizure threshold, an agonist would not be expected to increase seizure 
susceptibility. However, this hypothesis would require further investigation to 
confirm the safety and utility of such an approach in vivo.  
In the behavioral characterization of the BGT1 KO mouse, it was found that 
the KO mouse is less susceptible to pain induced by formalin injection, but no 
difference was observed in carrageenan-induced hyperalgesia or in paw edema 
following carrageenan injection. Two likely explanations exist for this observation. 
First, although both tests are models of inflammatory pain, they do produce 
hyperalgesia by differing mechanisms. Formalin activates a member of the 
Transient Receptor Potential family of cation channels, the TRPA1 cation 
channel, to induce hyperalgesia (McNamara et al. 2007), while a specific 
receptor has not been identified in the carrageenan-induced response. 
Hyperalgesia develops more slowly in the carrageenan test and involves a 
phenomenon termed “windup,” in which the number of neuronal responses 
progressively increases (Mendell 1966). Windup is involved in the maintenance 
of inflammatory and neuropathic pain and is attributed to responses of spinal 
dorsal horn neurons evoked by C-fiber afterdischarge (Dubner 1986; Gracely et 
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al. 1992). In contrast, the formalin test produces a rapid pain response that, at 
the acute times investigated, precedes the windup phenomenon. Second, the 
formalin test was performed in kindled mice while the carrageenan test was 
performed in naïve mice. It is a distinct possibility that the process of kindling 
differentially affected the pain threshold of WT and KO mice, and that, under 
these particular conditions, a difference in inflammatory pain exists between 
genotypes. This may be the most likely explanation for the contradictory results 
obtained. It was expected that, if a pain phenotype existed, it would be 
determined by the writhing test, which is the most sensitive pain test (Hendershot 
and Forsaith 1959; Collier et al. 1968). However, the writhing test did not 
determine a difference between genotypes. The results obtained in pain assays 
were unexpected, and may be a result of genetic variability as discussed below. 
Further investigation is necessary to determine what role BGT1 plays in the 
modulation of pain. In the future, the formalin test must be performed in naïve 
animals and paw edema measured. It may also be of interest to investigate the 
role of corneal kindling in pain modulation if no difference between genotypes is 
found in naïve mice.  
It must be kept in mind when interpreting data obtained with genetically 
altered mice that WT and KO mice are not coisogenic, meaning they do not differ 
only in the targeted gene. Rather, genes that are on the same chromosome as 
the transgene are linked to the transgene and become hitchhiking donor genes 
(Crusio 1996). Mice for the current study were bred on a mixed 129/SV and 
C57/B6 background. Hitchhiking donor genes will be 129/SV-derived in KO mice 
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(since the transgene was derived from 129/SV embryonic stem cells) and 
C57/B6-derived in WT mice. Even after 12 generations of breeding, up to 300 
hitchhiking genes may remain. Hence, phenotypic differences observed in KO 
mice may actually be due to differential alleles in these neighboring genes 
between mouse strains (Gerlai 1996). Hitchhiking genes are particularly 
confounding in pain studies, because 1) 129/SV and C57/B6 mice differ 
significantly in pain responses, and 2) C57/B6 mice are a poor representative 
species for pain studies, as they are clear outliers regarding many pain-related 
traits (Mogil et al. 2001).  The existence of possible strain differences does not 
explain the lack of effect of dAMPH on BGT1 KO mouse locomotion, because 
both C57/B6 mice and 129/SV mice have been reported to experience significant 
hyperlocomotion in response to dAMPH (Gould et al. 2007). Strain differences 
also do not explain the increased basal locomotion of KO mice, because 129/SV 
mice are less mobile under basal conditions than C57/B6 mice. dAMPH/CDZP 
hyperlocomotion in 129 mice is not attenuated by 100 mg/kg lithium, while it is 
significantly reduced in C57/B6 mice (Gould et al. 2007). These results are not 
consistent with the observation that basal locomotion of BGT1 KO mice (more 
129/SV genes vs WT mice) is significantly attenuated by 100 mg/kg lithium while 
WT locomotion is not. In the future, the combination of dAMPH/CDZP and lithium 
must be determined in WT and KO mice as performed by Gould et al. (2007). In 
the FST, C57/B6 mice display much higher immobility times than 129/SV mice 
(Lucki et al. 2001). This does not explain the current FST results, because WT 
mice were more mobile than KO mice. If a background strain effect were indeed 
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responsible for the obtained results, it would be expected that WT mice would be 
less mobile in the FST and more mobile in the locomotor test area than KO mice 
due to a higher proportion of C57/B6-derived genes. In contrast to the findings in 
the FST and locomotor tests, the results of the light-dark test are consistent with 
studies comparing 129 (more similar to KOs) and C57/B6 (more similar to WT) 
mice (Holmes et al. 2003).  Therefore, the anxiety-like phenotype of the BGT1 
KO mouse may be background strain-related.  
From the strain differences existing between C57/B6 and 129/SV mice, it is 
clear that the data obtained in the current study should not be over-interpreted. It 
is possible that the variable genetic background of each mouse significantly 
contributed to the findings in this study, although the known strain differences 
between C57/B6 and 129/SV mice are not predictive of the outcomes presently 
obtained. Nonetheless, in the future, the BGT1 WT and KO mice must be further 
backcrossed to a pure strain and the experiments repeated. Although hitchhiking 
genes will remain an issue as discussed above, there will be less genetic 
variability present than in the current study. Alternatively, more sophisticated 
genetic tools and a BGT1-specific inhibitor would allow for a more clear 
determination of a role for BGT1 in CNS disorders.  
The BGT1 KO mouse had similar seizure thresholds to those of WT mice in 
several diverse tests. However, other GABA-related behaviors do suggest a role 
for BGT1 in the CNS. Future studies involving pharmacological modulation of 
BGT1 or more sophisticated genetic modulation of BGT1 are necessary. 
However, the current study describes a potential role for BGT1 in the modulation 
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of depression, anxiety, and neuropsychiatric disorders with a low risk of motor 
and cognitive side effects. Further investigation of BGT1 in the modulation of 
neuropsychiatric disorders is warranted.  
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Aim and significance 
The studies presented in this dissertation were designed to test the 
hypothesis that BGT1 plays a role in epilepsy, seizure control, and certain 
behaviors, including depression, anxiety, pain, cognition, and motor activity. This 
hypothesis was based upon several findings: 1) BGT1 transports both the major 
inhibitory transmitter in the mammalian CNS, GABA, and the organic osmolyte, 
betaine (Lopez-Corcuera et al. 1992). Both inhibitory tone and osmotic balance 
play a role in controlling neuronal excitability, making BGT1 a potential target for 
modulation of excitability; 2) EF1502, an equipotent inhibitor of GAT1 and BGT1, 
displayed synergistic anticonvulsant action in the absence of increased toxicity 
when combined with TGB, a GAT1 selective inhibitor (White et al. 2005; Madsen 
et al. 2009). Synergism is most easily explained by the existence of two 
functional mechanisms of action, i.e., both GAT1 and BGT1 inhibition; 3) EF1502 
reduced the frequency of spontaneous bursting in brain slices held in a 
hyperexcitable medium, while TGB failed to produce a similar response. Hence, 
it was suggested that this effect was related to BGT1 inhibition by EF1502 (Smith 
et al. 2008); 4) several neurological conditions are influenced by GABAergic 
modulation, including pain, anxiety, depression, and other neuropsychiatric 
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disorders (Benes and Berretta 2001; Jasmin et al. 2004; Kalueff and Nutt 2007). 
To address the hypothesis that BGT1 is involved in epilepsy, we determined 
whether BGT1 mRNA expression was altered in a model of temporal lobe 
epilepsy, which may suggest engagement of this target in epilepsy. To determine 
if BGT1 is involved directly in seizure control and behavior, both a 
pharmacological inhibitor of BGT1 and a BGT1 knockout mouse were utilized. 
Studies to determine a direct role for BGT1 in acute seizure control involved the 
determination of the seizure threshold of BGT1 WT and KO mice using four 
different seizure models. Behavioral characterization of the BGT1 KO mouse 
included models of depression, anxiety, pain, motor coordination, and 
locomotion. In vitro testing included long-term potentiation determinations in 
freshly isolated hippocampal slices obtained from BGT1 KO and WT mice. 
Results obtained from this approach and described in this dissertation provide 
insight into the potential involvement of BGT1 in epilepsy and several other CNS 
disorders, and lend support to the hypothesis that BGT1 modulation may be 
useful for the clinical treatment of neurological disorders.  
 
Summary and conclusions 
Chapter 2 describes the temporal expression pattern of BGT1 in the 
hippocampus following SE. The patterns of other GATs and osmoprotective 
genes were also determined and compared to those of BGT1. In the pilocarpine 
SE model, mRNA expression was upregulated early post-SE along with other 
osmolyte transporters, but was downregulated along with the GABA transporters 
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at later time-points. These results suggest that BGT1 may possess functionality 
as both a GABA and an osmolyte transporter in the CNS. It was determined that 
TonEBP does not exert full control over the expression of BGT1 and the other 
osmoprotective genes in the brain. TonEBP also does not induce osmoprotective 
gene expression in response to inflammation, despite its upregulation by an 
inflammatory stimulus. This is consistent with results obtained in studies 
performed outside the CNS (Atta et al. 1999; Trama et al. 2000).  The results 
from the current dissertation are in agreement with and expand upon several 
observations in the literature that suggest that TonEBP is not the major 
transcription factor responsible for the expression of osmoprotective genes in the 
brain: 1) TonEBP displays differential expression patterns in the brain compared 
to the osmoprotective genes with regard to cell type, region, and expression level 
(Maallem et al. 2006a); 2) TonEBP and osmoprotective gene expression vary by 
tissue (Zhang et al. 2003); 3) TonEBP is only present and hypertonic-inducible in 
neurons, while other neuronal cells display upregulation of the osmoprotective 
genes in response to osmotic stress (Loyher et al. 2004; Maallem et al. 2006b). 
Dehydration and inflammation do not account for the BGT1 alterations seen post-
SE; however, inflammation may contribute to the downregulation of GAT1 and 
GAT3. These results are again in agreement with previous findings suggesting 
that GAT1 is modulated in the CNS by inflammation (Wang et al. 2008). Although 
the molecular regulation of BGT1 in the brain remains unknown, this dissertation 
determined that BGT1 is altered by SE in a manner similar to both GATs and 
osmolyte transporters. Since both GABAergic inhibition and osmotic balance play 
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roles in controlling neuronal excitability, further investigation into the role of BGT1 
in seizure control was warranted. 
The corneal kindled mouse model has been suggested to be a cost-effective 
model for the determination of the anticonvulsant potential of investigative 
compounds against partial seizures (Matagne and Klitgaard 1998). However, the 
use of this model for the pharmacological characterization of a compound had 
not been fully validated. The results from this approach are described in Chapter 
3. ED50s for nine AEDs, as well as six investigational compounds, were obtained 
in the corneal kindled mouse model of partial seizures as well as in the MES, 6 
Hz, scPTZ, and rat hippocampal kindling models. Results obtained in the corneal 
kindling model demonstrated positive correlations with those attained using 
established preclinical models. Hence, the corneal kindling model represents a 
sensitive and valid preclinical screening tool for the identification of 
anticonvulsant compounds.  
In Chapter 4, the corneal kindling model, along with the 6 Hz, MES, scPTZ, 
and Frings mouse models, were utilized to determine the pharmacological profile 
of a BGT1 specific inhibitor, Hit 8. Hit 8 was identified as a specific BGT1 inhibitor 
using a library screening method (Bolette Christiansen, unpublished). This 
method was utilized because structural-based methods to identify inhibitors may 
predispose to identifying compounds that are nonspecific due to a well-
conserved substrate-binding site among the GATs (Beuming et al. 2006). Hence, 
utilizing substrates as scaffolds often leads to the identification of nonspecific 
compounds.  
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Hit 8 was tested for anticonvulsant, antinociceptive, and antidepressant 
activity because GABAergic modulation is known to be involved in these 
behaviors. The anticonvulsant profile of Hit 8 was determined to be different from 
that of TGB, making it potentially useful for the clinical treatment of different 
seizure types than TGB. Unfortunately, Hit 8 has a very narrow therapeutic 
window for the treatment of seizures. However, at doses well below toxicity Hit 8 
was efficacious as both an antidepressant and an analgesic compound. Although 
these results may be expected from a compound that increases GABAergic tone 
by inhibiting the reuptake of GABA, it was determined that Hit 8 is in fact not a 
selective BGT1 inhibitor by the National Institute of Mental Health's Psychoactive 
Drug Screening Program. It was determined that Hit 8 possesses high affinity for 
several targets of physiological relevance in seizures, pain, and depression. 
These include receptor subunits from the serotonin, dopamine, muscarinic, and 
histamine families, as well as the mu opiod receptor. Due to the high affinity of 
Hit 8 for these targets, it seems improbable that BGT1 inhibition plays a role in 
the mechanism of action of Hit 8. Without an available BGT1 specific inhibitor, a 
mouse lacking BGT1 became the only available tool for the investigation of the 
role of BGT1 in seizures and behavior.  
The results presented in Chapter 5 were obtained from mice that were 
genetically engineered to lack functional expression of BGT1 protein (Lehre et al, 
unpublished). Results from these BGT1 KO mice were compared to those 
obtained from WT littermate controls. Using four different models of seizure 
threshold (minimal clonic, 6 Hz, minimal tonic extension, and i.v.PTZ thresholds), 
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it was determined that BGT1 is not directly involved in determining acute seizure 
susceptibility in the current BGT1 KO mouse. This was unexpected and 
stimulated further investigation into possible developmental compensatory 
mechanisms in the BGT1 KO mouse. No upregulation of other GABA 
transporters or osmolyte transporters was observed in these mice. However, this 
does not preclude the existence of other compensatory mechanisms. For 
example, the GAT1 KO mouse does not display upregulation of GAT3, but does 
display alterations in GAD65/67, GABAB receptors, and GABA release 
characteristics (Jensen et al. 2003; Xu et al. 2007; Bragina et al. 2008). With no 
obvious compensation in the BGT1 KO mice, more subtle behavioral phenotypes 
warranted investigation. It was determined that the BGT1 KO mouse is not 
different from WT mice in long-term potentiation or motor coordination. Plasma 
osmolality was also not different between genotypes, ameliorating the concern 
that global alterations in osmolality between the two genotypes were masking 
differences in seizure threshold. For example, BGT1 KO mice were expected to 
have a higher seizure threshold than WT mice due to an expected increase in 
extracellular GABA. Since no difference in seizure threshold was ascertained, it 
was a concern that KO mice may have systemic hyposmolality, which would 
cause cell swelling in the CNS and mask an increased seizure threshold in the 
KOs by increasing excitability. Plasma osmolality measurements negated this 
concern.  
Several differences were demonstrated between the WT and BGT1 KO 
animals. The BGT1 KO mouse may have a pain-related phenotype, although 
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conflicting results were obtained in the different preclinical models utilized. Since 
each nociceptive test signals through a different pain pathway, conflicting results 
may be expected, but must be confirmed with the performance of each test in 
naïve animals. It was presumed that the writhing test would determine a 
difference between genotypes if one existed, since it is the most sensitive pain 
test (Hendershot and Forsaith 1959; Collier et al. 1968). The BGT1 KO mouse 
appears to have a depressive-like phenotype in the FST that is not explained by 
possible strain differences, because 129SV mice swim more than C57/B6 mice 
(Lucki et al. 2001), and KO mice possess a higher proportion of 129SV genes 
than WT mice. The FST results are also not explained by general hypoactivity of 
the BGT1 KO mouse. In fact, BGT1 KO mice displayed basal hyperlocomotion 
that was attenuated by lithium, and not further increased by CDZP/dAMPH. The 
locomotor profile of the BGT1 KO mouse is not consistent with what would be 
predicted if strain differences were contributing to the observed results, because 
129/SV mice are less mobile under basal conditions than C57/B6 mice, and 
dAMPH-induced locomotion is not attenuated by 100 mg/kg lithium in 129 mice 
(Gould et al. 2007), and KO mice possess a greater proportion of 129SV genes 
compared to WT mice. The BGT1 KO mouse was determined to possess an 
anxiety-like phenotype in the light-dark box. This phenotype is consistent with 
what would be expected from the respective background strains of the WT and 
KO mice (Holmes et al. 2003). The observed depressive and anxiety-like 
behavior and hyperlocomotion of the BGT1 KO mouse suggest that BGT1 
inhibition may produce undesirable side effects, despite the finding that cognition 
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is not expected to be altered based on the observed LTP results. This particular 
phenotype of the BGT1 KO mouse raises possible concerns regarding the future 
clinical utility of BGT1 inhibition if indeed the mouse FST accurately models 
human depression. To this point, a BGT1 agonist may be more useful clinically. 
In addition, the BGT1 KO mouse may potentially represent a genetic model of 
depression, anxiety, and/or neuropsychiatric disorders such as bipolar disorder 
and schizophrenia given the observed profile in the preclinical animal models 
utilized in this dissertation research. However, as discussed in Chapter 5, the 
results obtained with the current BGT1 KO mouse must not be over-interpreted 
due to several drawbacks of the technology and the possible significant effect of 
strain differences that exist between KO and WT mice. Nonetheless, the 
depression and locomotion results obtained were not consistent with those 
predicted by the responses of the wild type C57/B6 and wild type 129/SV mice, 
and do support the hypothesis that BGT1 plays a functional role in the CNS. The 
results from this dissertation provide evidence for continued investigation of 
BGT1 in CNS disorders.  
In summary, although BGT1 is not involved in the control of acute seizure 
activity, it appears to be involved in epilepsy as evidenced by alterations post-SE 
that are similar to both osmolyte and GABA transporters.  BGT1 is also 
potentially involved in the modulation of GABAergic behaviors such as pain, 
depression, anxiety, and neuropsychiatric disorders involving a manic phase, 
such as might be seen in bipolar disorder and schizophrenia. Further 
 163
investigation into BGT1 in both epilepsy and other disorders of the CNS is clearly 
warranted.  
 
Speculations and future directions 
BGT1 is an organic osmolyte transporter that contributes to osmoregulation in 
the brain. Seizure activity produces an ionic imbalance (Schwartzkroin et al. 
1998), and it is possible that an animal lacking the proper regulatory mechanisms 
to adapt to ionic alterations may have a reduced capacity to recover from such 
an insult. In the absence of the ability to modulate betaine uptake to compensate 
for ionic flux, cellular function would degrade and possibly lead to death following 
an increase in the intracellular ion concentration in BGT1 KO mice (Petronini et 
al. 1993; Burg 1994; Haussinger 1996). Hence, mice lacking BGT1 may 
experience increased cell death due to a reduction in the ability to efficiently 
regulate osmolality. On the other hand, if cell survival is unaffected, mice lacking 
BGT1 may have reduced astrogliosis if intake of water through BGT1 contributes 
to cell swelling post-SE (Zhu and Ong 2004).  
The results obtained in Chapter 5 suggest that BGT1 may play a functional 
role in the CNS and support putting forth the investment necessary to develop 
tools that will allow further study.  Although a purely selective pharmacological 
modulator would be of utmost utility, it has been so far impossible to obtain this. 
Therefore, several improvements are possible utilizing the genetic approach. The 
current BGT1 KO mouse could be bred onto a pure background to minimize 
strain effects. However, as discussed in Chapter 5, hitchhiking donor genes will 
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still be present (Crusio 1996). Furthermore, the C57/B6 strain may be a poor 
choice for a genetic background (Mogil et al. 2001). A conditional CNS knockout 
would perhaps be more useful (Gu et al. 1994), and may reduce the degree of 
developmental compensation; since osmoregulation is integral to sustain life and 
the osmoregulatory systems are extremely redundant (Yancey et al. 1982), 
BGT1 will most certainly be compensated for in a conventional knockout. A better 
solution to compensation is an inducible KO, in which BGT1 will be ubiquitously 
expressed until an agent is administered that ablates its expression (Kuhn et al. 
1995). Interfering RNA (RNAi) technology may also be useful (Tabara et al. 
1998). Here, RNAi could be directly injected or targeted to the CNS to reduce the 
expression of BGT1 (Mathupala 2009). In addition to genetic knockdown of 
BGT1, overexpression may also provide valuable information (Zhu et al. 1993).  
As discussed in Chapter 2, little is known of the regulation of BGT1 in the 
brain. In the future, the development of a specific BGT1 antibody with a low 
detection limit that could identify BGT1 in the CNS would be advantageous for a 
number of reasons. This would finally mitigate the debate regarding the exact 
localization patterns of BGT1 in the brain. Furthermore, it would allow the 
regulation of BGT1 in the CNS to be investigated directly. As discussed in 
Chapter 2, TonEBP does not appear to exclusively control BGT1 expression in 
the brain. It is possible that alternate transcription factors are binding to the TonE 
sites in the promoter region of the BGT1 gene. It is also possible that other 
promoters are responsible for the control of BGT1 expression in the brain. Eight 
BGT1 isoforms exist, which differ in their 5’ untranslated region and tissue 
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distribution suggesting that different promoters may be involved in a tissue-
specific manner (Takenaka et al. 1995). Hence, it is possible that a promoter 
distinct from TonE1 and 2 exists and is functional in the brain. BGT1 tagged with 
enhanced green fluorescent protein could be transfected into neurons and glia in 
vitro to determine the trafficking and subcellular distribution of BGT1, similarly to 
what has been done in kidney cells (Kempson et al. 2003). Furthermore, if a 
specific antibody were available, co-immunoprecipitation studies could be 
performed to elucidate what BGT1 is binding to in the CNS under conditions of 
upregulation. In utero electroporation techniques could be utilized to tag and 
investigate BGT1 in vivo (Shimogori and Ogawa 2008).  
The function of BGT1 in the brain is also unclear. Since it appears from 
behavioral studies that BGT1 may be involved in the modulation of depression 
and neuropsychiatric disorders, it may be of interest to investigate the effect of 
BGT1 knockdown on systems known to be involved in these disorders. For 
example, the GABAergic system exerts effects on the dopaminergic and 
serotonergic systems (Soubrie et al. 1981; Nestler et al. 2001); it is possible that 
levels of these transmitters or of the transporters for these molecules are altered 
by BGT1 activity. Four general possible functions of BGT1 in the CNS were 
suggested in Chapter 5.  
1) Osmotic or GABAergic regulation.  To assess whether BGT1 is functionally 
a betaine transporter, a GABA transporter, or both, in vivo in the CNS, 
measurements of these substrates could be taken before and after knockdown of 
the gene using microdialysis. Although plasma osmolality was not different 
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between BGT1 KO and WT mice, osmolality of the brain’s interstitial fluid may be 
different and may be measured from the dialysate. Electrophysiological studies 
would provide useful information regarding the effect of BGT1 on inhibitory and 
excitatory neurotransmission. Unfortunately, it is not expected that the BGT1 KO 
mouse has the ability to elucidate whether BGT1 plays a significant osmotic role 
in the brain because the system is extremely redundant (Yancey et al. 1982), and 
because betaine is not considered one of the major osmolytes in the brain 
(Gullans and Verbalis 1993). Hence, the effect of BGT1 may not be observable 
unless the other osmotic systems are blocked. This does not preclude, however, 
that betaine may indeed contribute to the overall osmotic balance in the brain, a 
fact that is supported by a reported increase in brain levels of betaine following 
systemic salt-loading (Lien et al. 1990).   
2) GABA and/or betaine transport across the blood-brain barrier. The 
development of an adequate antibody would strengthen the argument that BGT1 
is located at the BBB (Takanaga et al. 2001), from where it would be uniquely 
positioned to participate in the flux of GABA (Zhang et al. 1999; Kakee et al. 
2001). BGT1 is also a likely homeostatic regulator of betaine levels in the brain 
due to its localization at the BBB. Regulation of betaine uptake and efflux through 
the BBB allows the brain to be the only tissue in which betaine levels are below 
plasma levels (50 µM in brain vs 190 µM in plasma in rats) (Slow et al. 2009). 
Betaine levels are increased in the brain following salt-loading (Lien et al. 1990), 
and pediatric patients treated with betaine for longer than 4 weeks have been 
reported to experience cerebral edema (Yaghmai et al. 2002; Devlin et al. 2004). 
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Although this edema may represent uptake by BGT1, it may also reflect the 
osmotic opening of the BBB (Kroll and Neuwelt 1998) and successive betaine 
entry. Nonetheless, the current evidence suggests that betaine levels in the brain 
are dynamically controlled, very likely by BGT1. Although it is believed that 
betaine in the brain predominantly originates from the plasma, betaine can be 
synthesized in the brain through choline oxidation (Katz-Brull et al. 2005). It can 
also be transported by amino acid transport system A, which is present at the 
BBB (Petronini et al. 2000; Smith 2000). Previous studies have determined BBB 
transport of GABA, excitatory amino acids, and taurine (Tamai et al. 1995; 
Hosoya et al. 1999; Kakee et al. 2001). Similar studies in a controlled in vitro 
expression system could be utilized to determine whether BGT1 is the major 
transporter responsible for the BBB efflux of betaine.  
3) Redistribution of betaine following osmotic stress and/or the redistribution 
of GABA from GABAergic to glutamatergic neurons. To assess if BGT1 
possesses the ability to redistribute betaine in the brain following osmotic stress 
or seizure activity, methods similar to those employed to determine the 
redistribution of taurine could be utilized (Nagelhus et al. 1993). It has recently 
been suggested that BGT1 contributes to the redistribution of GABA from 
GABAergic to glutamatergic neurons (Sunol et al. 2010). The availability of the 
BGT1 KO mouse provides an integral control that would greatly strengthen 
conclusions regarding the contribution of BGT1 to redistribution of substrates. 
 4) Functionality as a neurotransmitter-gated ion channel. Electrophysiological 
methods similar to those utilized to determine that GAT1, EAAT4, and EAAT5 
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can behave as “neurotransmitter-gated ion channels” (Fairman et al. 1995; 
Sonders and Amara 1996; Arriza et al. 1997; Bagley et al. 2005; Wersinger et al. 
2006) could be employed to ascertain a similar function for BGT1 if a specific 
pharmacological inhibitor for BGT1 were developed.  This ion channel function 
may be particularly relevant for BGT1, which transports three sodium molecules 
per transport cycle as compared to two sodium molecules transported by GAT1 
(Matskevitch et al. 1999). Hence, several potential functions of BGT1 in the CNS 
remain to be investigated.  
The results presented in this dissertation are the first to demonstrate 
alterations in the molecular regulation of BGT1 in the brain (as well as the 
osmoprotective genes and TonEBP) following seizure activity and inflammation. 
Furthermore, it provides the first body of evidence that supports a role for BGT1 
in the CNS obtained in a BGT1 KO mouse. The studies contained herein have 
significantly contributed to our understanding of BGT1 mRNA expression in the 
CNS, and have elucidated several CNS disorders that BGT1 may be involved in. 
Although BGT1 does not appear to be involved in the acute regulation of seizure 
threshold, it does appear to be involved in the chronic condition of epilepsy. 
Moreover, BGT1 appears to play a potential role in pain, depression, anxiety, and 
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